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Radiolabeled receptor-binding peptides have emerged as an important class of
radiopharmaceuticals for diagnostic imaging and cancer therapy. Following radionuclide
labeling, the specific receptor-binding properties of the ligand can be exploited to guide
the radioactivity to tissues expressing a particular receptor. This dissertation reports on
the development of integrin αvβ3–targeting radiopharmaceuticals for medical imaging
applications from the perspective of both the radiometal-labeled chelator as well as the
targeting peptide. Several macrocyclic copper(II) chelators have been studied with the
goal of improving kinetic and in vivo stability. Structurally diverse bifunctional RGD
(arginine-glycine-aspartic acid) peptides were investigated for αvβ3 integrin affinity in vitro
and in vivo. The goal of accomplishing higher binding affinity through multivalency has
been pursued by evaluating the binding affinity of nanoparticles presenting multiple
peptides on their surface.
Copper radionuclides have been the subject of considerable research effort
because they offer a varying range of half-lives and positron energies, making them
useful for diagnostic imaging and/or targeted radiotherapy. Ensuring the stability of metal
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complexes in vivo remains a challenge in the development of radiometal-based
radiopharmaceuticals. Reported here are data on the in vitro and in vivo evaluation of
three macrocyclic chelators, C3B-DO2A, CB-TR2A, and NOTA. These studies were
performed to improve Cu(II) complexation kinetics while retaining the high in vivo
stability of our lead chelating agent, CB-TE2A. Optimal radiolabeling conditions were
established for the 64Cu-labeled radiometal chelators and their in vivo biodistribution and
excretion were studied in normal rats.
Integrin αvβ3 is upregulated in tumor vasculature, osteoclasts, and areas of
collateral circulation following ischemic injury. A series of structurally diverse bifunctional
RGD (arginine-glycine-aspartic acid) peptides were investigated for αvβ3 affinity in vitro
and in vivo. The RGD-peptide analogs were screened for affinity to the αvβ3 integrin and
specificity compared to αvβ 5 and αIIbβ3. Extent of internalization of these peptides by an
αvβ 3 expressing cell line, U87MG human glioblastoma cells, was determined. The
compounds were screened via biodistribution studies and microPET imaging of a murine
U87MG tumor model.
Polyvalence has known to have a profound effect on receptor-binding affinity and
in vivo kinetics of radiolabeled multimers. The goal of accomplishing higher binding
affinity through multivalency has been pursued by evaluating the binding affinity of shell
cross-linked (SCK) nanoparticles presenting multiple RGD peptides on their surface.
Difficulties encountered in obtaining nanoparticles with high levels of bioavailable
targeting peptide on the surface led to a systematic study of methods of shell
functionalization and particle purification with chemical, physical, and biological
evaluation of each compound.
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The development of radiometal-labeled peptides is a relatively slow process, thus
in this research, optimization of various aspects was studied in parallel. Each chapter
presents a small contribution, but the knowledge gained from these studies can be taken
together to produce radiopharmaceuticals with optimal properties—high in vivo stability,
high uptake in tumors, low uptake in non-target tissues, and rapid blood clearance,
preferably through renal excretion.
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CHAPTER 1

Introduction
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Molecular Imaging
Molecular imaging has distinguished itself as an interdisciplinary field drawing
from chemistry, biology, physics, and medicine. The fact that a collaborative effort
among several professional societies was under taken to define molecular imaging
emphasizes its broad reach. “Molecular imaging is the visualization, characterization,
and measurement of biological processes at the molecular and cellular levels in
human and other living systems. To elaborate: Molecular imaging typically includes
2- or 3-dimensional imaging as well as quantification over time. The techniques
include radiotracer imaging/nuclear medicine, MR imaging, MR spectroscopy, optical
imaging, ultrasound, and others.”1 It has impacted clinical medicine and
pharmaceutical development. Physicians can generate high-resolution images of the
human body non-invasively, diagnose ailments, and prescribe or monitor treatment
regimens based on them. Scientists involved in drug discovery can accelerate the
screening process in pre-clinical drug development. Molecular imaging can facilitate
determinations of desired and undesired pharmaceutical side effects, analyze drugtarget interactions, and evaluate delivery absorption, distribution, metabolism, and
elimination in vivo. Its utility in studying drug action, establishing dosing regimens
and treatment strategies will eventually provide the means to accomplish
“personalized medicine” by monitoring individual response to drug delivery.2
Molecular imaging differs from traditional imaging in that biomarkers are used
to help image particular targets or pathways. Biomarkers are characteristics that are
objectively and quantitatively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention. They interact chemically with specific components in their
surroundings allowing imaging of physiological changes, altering the image
according to molecular changes occurring within the area of interest. This process is
markedly different from older methods of imaging, such as x-ray and magnetic
resonance imaging (MRI), which primarily image differences in qualities such as
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density or water content. The ability to image fine molecular changes opens up
numerous exciting possibilities for medical and research applications. Furthermore,
molecular imaging allows for quantitative tests, imparting a greater degree of
objectivity to these imaging studies.
Nuclear medicine is a medical field that employs molecular imaging through
the use of radioactive agents (e.g. radiopharmaceuticals) for the purpose of
diagnosis and therapy of disease. By imaging the distribution of radioactivity in the
subject, physicians can non-invasively provide useful information about metabolism,
blood flow, inflammation, and receptor status as well as location, size, and extent of
diseased tissues. Radiopharmaceuticals are created by the incorporation of
radionuclides into compounds tailored for biological targeting. This non-invasive
imaging relies on the external detection of the emitted radiation by cameras
surrounding the subject. The intrinsic properties of the radionuclide utilized determine
the value of an agent for imaging or therapy, in addition to determining the
appropriate imaging modality—gamma camera, single photon emission computed
tomography (SPECT) or positron emission tomography (PET). A gamma camera
gives planar images, whereas SPECT and PET provide three-dimensional images.
In the research described here, PET imaging, which utilizes positron-emitting
radionuclides, is used to investigate in vivo biological processes non-invasively.
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Positron Emission Tomography
PET allows for non-invasive construction of static anatomical images as well
as the collection of dynamic, real-time images of a biochemical process. PET images
are obtained following intravenous (IV) injection of a positron (β+) emitting
radiopharmaceutical whose biochemical behavior and biological distribution are well
characterized. The development of novel positron-emitting radiopharmaceuticals with
desirable clearance and pharmacokinetic properties is a growing field of research.3
Radioactive decay occurs as part of the process of balancing an unstable
nucleus’ proton/neutron ratio. Proton-rich isotopes undergo a process that will lower
this ratio and result in a stable nucleus. One method is through the addition of energy
to convert a proton (p) into a neutron (n), neutrino (υ) and a positron (β+) (Equation
1).

p → n +ν + β +

(Eq. 1)

The new element recoils from the event, and the positron and neutrino are emitted at
high speed. The positron, a positively charged electron, collides with electrons as it
travels through the surrounding matter losing kinetic energy. Once most of the
energy has been lost, the positron associates with an electron, which has an
opposite charge but equal mass, and both particles annihilate. The particles’ masses
are converted into energy in the form of two 511 keV photons, emitted in opposite
directions, almost 180º apart from each other (Figure 1). These annihilation photons
can be detected by coincidence circuitry consisting of a solid scintillation crystal
coupled to a photomultiplier tube (PMT). The energy of the positron determines the
distance traveled by the particle prior to annihilation. Higher ejection energy
corresponds to a greater distance traveled before annihilation. This distance, known
as the positron range, affects image resolution.
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Figure 1. A positron is emitted from an unstable proton-rich nucleus. After traveling a
short distance, it annihilates upon contact with an electron. This releases two
photons approximately 180° apart.

A PET scanner consists of an array of detectors surrounding the subject,
connected through coincidence circuitry. A decay event is recorded when a pair of
photons are received at connected detectors within a certain time frame (Figure 2).
The exact site of the annihilation is unknown, but by acquiring a large number of
coincidence events recorded across all detector combinations, sufficient information
is obtained for complex computer algorithms to reconstruct the numerous events that
have been registered into an image with information on the spatial distribution of
radioactivity as a function of time. Several factors affect image resolution, including
positron range, photon attenuation, and random coincidences from scattered and
random photons. Once corrections for photon attenuation and random, scattered
radiation have been made, the measured tissue radioactivity can be reported in
absolute units, such as Becquerel (Bq)/mL. Correlation of PET images with
anatomical imaging modalities, such as CT and MRI, can aid in accurate
identification of tissues with enhanced uptake.4
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Gamma rays

Figure 2. Cartoon of a human PET scanner. A circular array of detectors surrounds
the patient and records sets of co-incident photon pairs.

Biomedical research usually involves extensive pre-clinical evaluation prior to
approval for human use. Animal models are employed in radiopharmaceutical
development. Human PET scanners have insufficient resolution for small animal,
such as rodent, imaging. A small animal PET scanner called microPET has better
sensitivity and image resolution for imaging in rodent or other small animal models.5
Additionally, microPET systems are more compact and cost less than clinical PET
systems. As with human PET images, microPET and micro-computed tomography
(microCT) images can be co-registered to enhance anatomical resolution in small
animal imaging.
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Targeted Radiopharmaceuticals
Radiopharmaceuticals are radioactive compounds used in nuclear medicine
for diagnosis and therapy. There are two broad categories of radiopharmaceuticals:
substrate specific and non-substrate specific agents. The more common, substratespecific radiopharmaceuticals are designed to target a specific biological process,
receptor or other type of protein expressed in distinct regions of the body.
Radiolabeled peptides have been extensively investigated for targeting overexpressed receptors on tumor cells and at sites of cardiovascular injury and repair.
Targeted radiopharmaceuticals are useful for diagnostic imaging as well as for
predicting response to a therapeutic regimen such as chemotherapy or targeted
radiotherapy. Depending on the mode of radioactive decay of the radionuclide, these
or analogous compounds can also be used for targeted radiotherapy.
Selection of the proper radionuclide in radiopharmaceutical design is
important and depends on several factors. The half-life should allow for sufficient
uptake and decay to yield contrast and quality images.6 The mode of decay and
energies of the radionuclide emission should be suitable for detection by the chosen
imaging modality. Radiopharmaceuticals incorporating β+ or γ emitting radionuclides
are useful for PET or SPECT imaging, respectively. Cost and availability should also
be considered.
There are a variety of commonly used positron emitting radionuclides with
various energy profiles and half-lives. The most widely used isotope for PET
radiopharmaceuticals is 18F due to practicality of transport with a half-life of 109.8 min
and ideal average β+ energy.7 The only FDA approved tracer for oncologic imaging is
[18F]2-fluoro-D-deoxyglucose (FDG), a radiolabeled glucose derivative.8 FDG, the
most common targeted PET imaging radiopharmaceutical, is taken up by glucoseutilizing cells and retained following phosphorylation by hexokinase. It is used for
studying cerebral, myocardial, and tumor glucose metabolism; however, the
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specificity of FDG is compromised due to uptake by inflamed and infected tissues as
well as by metabolically active tumors.
Radiolabeled peptides are good alternatives to FDG, as certain peptidebased agents specifically target receptors that are overexpressed by specific tumor
cells. Peptides have many of the favorable characteristics of small molecule
radiotracers, namely rapid blood clearance and tissue penetration, and low
antigenicity. However,

18

F cannot be readily incorporated into peptides and

antibodies as targeted radioligands.8 The short 119 min half-life of

18

F, typical 2 h

synthesis that includes HPLC purification, and resultant low yield are not ideal for
radiopharmaceutical production. Due to the larger size of peptides, metals can be
more readily attached to peptides via coordination by covalently bound chelators.
This additional functional group typically has well established radiolabeling chemistry
and its attachment often has no significant effect on peptide binding to target
receptors. Also, the diversity of half-lives of radiometals allows the physical half-life
of the isotope to be matched to the biological half-life of the radiopharmaceutical.9
Therefore, the development of radiometal-based agents is an active area of
research.

Copper-64
Copper radionuclides have been the subject of considerable research effort
because they offer a varying range of half-lives and positron energies, making them
useful for diagnostic imaging and/or targeted radiotherapy (Table 1).10, 11 Their halflives range from 10 minutes to 62 hours; they decay by positron (β+) and/or betaminus (β-) emission. The biodistribution of these copper radionuclides can be
assessed externally via clinical positron or gamma imaging techniques.
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Table 1. Decay characteristics of copper radionuclides.8
t1/2
23.4 min

β- MeV (%)
---

β+ MeV (%)
2.00 (69%)
3.00 (18%)
3.92 (6%)

EC (%)
7.4%

61

3.32 h

---

1.22 (60%)

40%

62

9.76 min
12.7 h

Isotope
60
Cu

Cu

Cu
Cu

64

67

Cu

62.0 h

--2.91 (97%)
0.573 (38.4%) 0.655 (17.8%)
0.395 (45%)
0.484 (35%)
0.577 (20%)

---

2%
41%
---

γ MeV (%)
0.511 (186%)
0.85 (15%)
1.33 (80%)
1.76 (52%)
2.13 (6%)
0.284 (12%)
0.38 (3%)
0.511 (120%)
0.511 (194%)
0.511 (34.8%)
1.35 (0.6%)
0.184 (40%)

Positron-emitting radionuclides are produced on either accelerators or
cyclotrons. Typically, a target material is bombarded with a proton beam to produce
a (p, n) nuclear reaction. A proton is incorporated into the nucleus followed by the
release of a neutron, resulting in a proton rich, unstable radionuclide that undergoes
β+ decay, as previously described. At Washington University, no-carrier-added

64

Cu

is produced on a biomedical cyclotron in high yield and high specific activity.12 Briefly,
a gold disk target electroplated with enriched 64Ni is irradiated with 14.5 MeV protons
on a CS-15 biomedical cyclotron. The target is introduced to an automated
processing system, and the nickel is dissolved in heated 6 M hydrochloric acid
(HCl).13 The dissolved nickel is loaded on an ion chromatography column and
recovered for recycling. Copper-64 is eluted off using 0.5 M HCl and blown down
under argon.14
Copper-64 has a long history of applications as a biomedical tracer because
of its longer half-life and short positron range. The 12.7 hour half-life allows for
distribution of this nuclide from regional production centers to imaging centers that do
not have direct access to a cyclotron. Copper-64 decays 17.8% by positron emission
and has a β+ maximum energy of 0.655 MeV with an average energy of 0.28 MeV. It
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also decays by electron capture and β-; therefore, it has been studied as both a
diagnostic and therapeutic radionuclide.15 The β+ maximum energy of 0.655 MeV is
similar to 18F, so the resulting PET images are of high quality.16
Copper coordination chemistry is well described in the literature, facilitating
the development of copper-based radiopharmaceuticals.12 Copper is a first-row
transition metal that primarily exists in two oxidation states: Cu(I) and Cu(II). The
coordination geometry for Cu(I) complexes is almost always tetrahedral and remains
stable in aqueous solution when coordinated to soft donors, such as phosphines and
thoioethers. The labile nature of most Cu(I) complexes in solution makes them
unsuitable for radiopharmaceutical applications. The coordination number for Cu(II)
ranges from 4 to 6 depending on the denticity of the chelator. Four-coordinated Cu(II)
complexes are normally square planar while 5-coordinated Cu(II) complexes are
often square pyramidal. The 6-coordinated Cu(II) complexes have a distorted
octahedral arrangement with the apical donor atoms weakly bound to the Cu(II).
Jahn-Teller distortion causes axial elongation or tetragonal compression in these
complexes.17,

18

While Cu(II) complexes are often kinetically labile, they are less

labile to ligand exchange and are favored for incorporation in radiopharmaceuticals.

Design of Copper-64-labeled Radiopharmaceuticals
For target agents with a long biological half-life or those intended for targeted
radiotherapy, it is imperative that the complexes formed are highly kinetically and
thermodynamically stable to minimize accumulation of the radiometal in non-target
tissues. Ligands that form radiocopper complexes with superior kinetic inertness to
Cu(II) decomplexation are favored over thermodynamic stability because this is more
significant following injection of the radiopharmaceutical into a living organism.
Reduction of Cu(II) to Cu(I) followed by Cu(I) loss may be another mode of
radiocopper loss, so resistance of the complex to Cu(II)/Cu(I) reduction and
reversibility can also be important. Rapid complexation kinetics are favored to allow
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for easy formation of the metal-chelator complex. Finally, the design of chelators
should incorporate available functional groups for covalent linking to targeting
peptides, proteins, and antibodies. A ligand consisting of a functional group for
attachment to the targeting moiety and a metal complexing ligand is a bifunctional
chelator (BFC) (Figure 3).9, 19, 20

Figure 3. Schematic of a radiopharmaceutical showing a bifunctional chelator (BFC)
to complex the radioactive metal ion attached to a targeting moiety, such as a
peptide.
The design of BFCs for copper has focused on macrocyclic chelators that
form kinetically stable and kinetically inert Cu(II) complexes. Copper(II) complexes of
linear polyaminopolycarboxylate ligands such as ethylenediaminetetraacetic acid
(EDTA) and diethylenetriaminepentaacetic acid (DTPA) have been shown to have
rapid transchelation of the Cu(II) to human serum albumin despite having high
thermodynamic stability.21,

22

Tetraazamacrocyclic chelators, such as cyclen

(1,4,7,10-tetraazacyclododecane) and cyclam (1,4,8,11-tetraazacyclotetradecane) as
well as their derivatives, have been shown to be significantly more stable in vivo.23
Two

N-functionalized

derivatives

of

cyclen

tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic

acid

and

cyclam,

(DOTA)

and

1,4,7,104,11-

bis(carboxymethyl)-1,4,8,11-tetraazabicyclousehexadecane (TETA) respectively, are
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commonly used examples (Figure 4).24 These BFCs can be covalently attached to
the peptide by formation of an amide bond between one carboxylate arm of the
chelator and the peptide’s N-terminus, leaving three carboxylates for possible
coordination to the radiometal. Both TETA and DOTA have been attached to
peptides and proteins for labeling with copper radionuclides. Their kinetic stability in
vivo is far from ideal, with dissociation leading to higher concentrations of

64

Cu in the

blood and liver, which decreases the efficacy for imaging and therapy.24

Figure 4. Structures of tetraazamacrocyclic chelators, and three dimensional
representations of Cu(II)-DOTA, Cu(II)-TETA, and Cu(II)-CB-TE2A based on crystal
structures.

Endeavoring to develop more stable BFCs for copper radionuclides, a new
class of bicyclic tetraamines featuring ethylene cross-bridges has been recently
reported.25

The

radiocopper

complex

of

one

such

compound,

CB-TE2A

(4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane), demonstrates
improved blood, liver, and kidney clearance and more favorable biodistribution

12

compared to the standard copper chelates

64

Cu-DOTA and

64

Cu-TETA.26,

27

Metabolism studies in rats show that, compared to 64Cu-DOTA and 64Cu-TETA, 64CuCB-TE2A has increased stability and reduced transchelation of

64

Cu to liver

superoxide dismutase (SOD).28
Comparison of the structures of the Cu(II) complex of CB-TE2A with DOTA
and TETA shows distorted octahedral coordination geometry with the copper being
chelated by four nitrogens and two oxygens for each complex (Figure 4).27 However,
the coordinating atom arrangement around each Cu(II) is different. Cu(II)-TETA has
two trans-axial oxygens while the coordinating oxygens for Cu(II)-DOTA and Cu(II)CB-TE2A have a cis conformation. Cu(II)-CB-TE2A adopts a low strain conformation
with all four nitrogen lone pairs coming together in a cleft, allowing the Cu(II) to be
fully enveloped in a “clamshell” arrangement.27 Both Cu(II)-DOTA and Cu(II)-TETA
have two non-coordinating carboxylate arms that remain free for potential
conjugation to a targeting moiety, whereas Cu(II)-CB-TE2A has no free carboxylate
arms. While this affects the net charge of the cross-bridged macrocyclic complex, it
has been demonstrated that a single carboxylate arm is sufficient for in vivo stability.
Cross-bridged chelators have demonstrated improved kinetic and in vivo
stability; however, the radiolabeling conditions required for formation of
TE2A and

64

Cu-CB-

64

Cu-CB-TE2A-peptide conjugates are harsh. Biologically compatible

aqueous conditions are sufficient for radiocopper complexation by TETA (0.5 M
NH4OAc, pH 6.5 for 30 min at room temperature (RT)).29 For formation of
radiocopper cross-bridged chelator complexes, the chelator must be pre-incubated
for 30 min with excess Cs2CO3 in EtOH at 75º C with constant mixing before the
addition of

64

CuCl2 and then complexation is achieved by heating for 30 min at 75º

C.30 Cross-bridged chelator-peptide conjugates require somewhat milder labeling
conditions (0.1 M NH4OAc, pH 6.5 - 8 for 45-90 min at 95º C).31 In order to be
compatible with larger peptides or antibodies,

64

Cu-radiolabeling conditions would

require aqueous solution near physiological pH at or below 43º C. Thus,
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development of other kinetically stable and kinetically inert BFCs with favorable
labeling kinetics remains an active area of research.

Integrin αvβ3
Integrins are best understood to constitute an important class of cell adhesion
receptors. They are responsible for cell-matrix adhesion and signaling across the
membrane. Integrins and their ligands play key roles in development, immune
response, leukocyte traffic, hemostasis, cellular entry and exit, and cancer.32 The 18
known α subunits and 8 known β subunits associate non-covalently to form 24
integrin heterodimers (Figure 5).33, 34 Each of these appears to have a distinct, nonredundant function, as concluded from their ligand specificities and from phenotypes
of knockout mice.35
The αvβ3 integrin is expressed on the surface of a variety of cell types
including endothelial cells,36-39 platelets,40 osteoclasts,41 melanoma,42 and smooth
muscle.43 Although known as the “vitronectin receptor,” it binds a variety of
extracellular matrix proteins with the exposed RGD sequences including fibrinogen,
fibronectin, laminin, collagen, Von WIllibrand’s factor and osteopontin.42 From these
diverse sites of expression and ligands, it should not be surprising the diversity of
physiological roles ascribed to it: angiogenesis,44 apoptosis,45 and bone resorption.46
Induction of angiogenesis by a tumor or cytokine promotes the expression of αvβ3.
Angiogenesis is essential for the proliferation and metastatic properties of human
tumors. Unregulated neovasculature is also responsible for a variety of other
pathological processes such as restenosis,47 rheumatoid arthritis, and retinopothy.48,
49

Due to integrin αvβ3’s key role in many physiological processes, it has been

evaluated extensively as a drug target.50
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Figure 5. The integrin receptor family. Schematic representation of the mammalian
subunits and their αβ associations which can be considered in several subfamilies
based on evolutionary relationships and ligand specificity. RGD receptors are
indicated on the left-hand side. (Repinted with permission from R.O. Hynes.51)

The αvβ3 integrin has been targeted with RGD (Arginine-Glycine-Aspartic
acid) peptides for PET imaging because of its expression on neovasculature as well
as some tumor cells.52 At least one report demonstrates the ability to image αvβ3 on
neovasculature in an αvβ3-negative tumor, but other reports indicate that only αvβ3positive tumors are detected following injection of a radiolabeled RGD-peptide.
Neither the mechanism of αvβ3 involvement in tumor neoangiogenesis nor the ability
to image αvβ3 specifically on blood vessels is well-established. Additionally,
osteoclasts have high levels of αvβ3 expression where it is required for bone
resorption. Peptidomimetic αvβ3 antagonists have been found to reduce bone
resorption in vitro and in vivo. Administration of an αvβ3 antagonist prevented
hypercalcemia of malignancy in a mouse model of Leydig cell tumor, an effect due to
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inhibition of tumor cell secretion of osteoclast activating factors or direct inhibition of
osteoclasts.36

RGD Peptides
Proteins that express the RGD attachment sit together with the integrins that
serve as receptors for them and comprise a major recognition system for cell
adhesion. Because of its small structure, the RGD site can easily be reproduced with
peptides. Short peptides containing the basic RGD sequence can mimic cell
adhesion proteins in two ways. When coated on a surface, they can promote cell
adhesion, while in solution they block adhesion by serving as decoys. RGD peptides
that have not been specifically designed to be selective for binding to certain
integrins mimic a number of adhesion proteins and bind to more than one receptor.
The peptide can be quite specific in its activity, however. Conformation of the amino
acids is known to be important; changing the aspartic acid residue to the D-form
inactivates the peptide. Replacing the aspartic acid with a glutamic acid or the
glycine residue with an alanine reduces the activity of the peptide in cell attachment
assays by 100-fold or more.
Since the RGD-sequence is conserved in all native ligands, differences in
binding affinities and specificity can be obtained from slight modifications. The
flanking amino acid residues, especially the two positions following the aspartic acid,
are known to change binding affinity both by direct interaction of the residues with
the integrin as well as influencing peptide folding. Cyclization is a common technique
to improve binding properties because it confers rigidity on the structure. All selective
RGD peptides have at least one ring structure. Linear RGD peptides are highly
susceptible to degradation, due to reaction of the aspartic acid residue with the
peptide backbone. Non-natural peptide modifications, such as the introduction of Damino acids and replacement with peptidomimetic structures, have yielded RGD
peptide ligands with greater specificity and nanomolar or higher affinities. Multivalent
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RGD-protein conjugates demonstrate subnanomolar affinity for αvβ3-expressing
human umbilical vein endothelial cells (HUVEC), a 250-fold increase verses the
monomer. Furthermore, multivalency has been shown to facilitate internalization.
Carrier systems like liposomes, nanoparticles, and proteins bearing multiple RGD
peptides are therefore more likely to be internalized via receptor-mediated
endocytosis than single peptide constructs.

Nanotechnology
Nanotechnology is a rapidly expanding field, benefiting from multidisciplinary
efforts in research, development, and education. It is a broad field encompassing
everything from nanoscale phenomena and processes to societal studies of the
benefits and risks of nanotechnology. Conventionally, nanoscale materials are
defined as being man-made and having a size of 1 to 100 nm in at least one
dimension. Unusual physical, chemical, and biological properties can emerge in
materials at the nanoscale. These properties may differ in important ways from the
properties of bulk materials and single atoms or molecules. The size of nanoparticles
makes them capable of imitating many features of biological species, including
proteins, a feature being taken advantage of by scientists to probe cell structure and
function at the sub-cellular level. Advances in nanotechnology and medicine in the
past decade are allowing researchers to take advantage of many unique properties
of nanoscale materials for improved diagnosis and treatment of disease.
Nanomedicine is the application of nanotechnology to disease treatment,
diagnosis, monitoring and control of biological systems, as defined by the National
Institutes of Health (NIH). The goal of nanomedicine is to develop safer and more
effective therapeutic and diagnostic modalities. Because of the size and
supramolecular structure of nanoparticles, technologies utilizing nanoparticles have
much potential for improving cancer therapy. A primary attribute of nanoparticle
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delivery systems is their potential to enhance the tumor accumulation of anticancer
agents in tumor cells than healthy tissues.
Polymeric nanoparticles have attracted interest for their potential applications
in nanomedicine. Shell crosslinked nanoparticles (SCKs) mimic the amphiphilic coreshell morphology with a hydrophobic core contained within a hydrogel network. They
are prepared from self-assembly of amphiphilic block copolymers which are
subsequently crosslinked between the polymer chains located within a shell. SCKs
present many available sites for surface functionalization by attachment of a variety
of compounds, such as receptor-targeting ligands, cell penetrating peptides, and
chelators for radiolabeling. Guest molecules can be encapsulated by the hollowing of
the core by selective degradation of the polymer chains. The properties of SCKs are
tunable by control of size, shape, and particle composition, as has been
demonstrated previously by Murthy et al.52
Through a multidisciplinary collaboration between physicians and scientists at
Washington University, a concerted effort is underway to develop a group of wellcharacterized and versatile nanoscale agents for targeted drug delivery. Novel SCKs
with the peptide KCRGDC have been evaluated for their affinity for the αvβ3 integrin.

Summary of Research
Molecular imaging plays an increasingly important role in disease
management, from screening and diagnosis to treatment and follow-up. This is
dependent upon the development of robust and specific image contrast agents. The
goal of this dissertation is to develop novel radiometal-based radiopharmaceuticals
for medical imaging. This has been addressed from the perspective of both the
bifunctional chelators as well as the targeting moiety.
Stability of metal chelates in vivo is a considerable challenge but
consideration must also be paid to the complex formation kinetics. In this work,
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several macrocyclic copper(II) chelators have been studied with the goal of
developing a BFC with good complex formation kinetics and in vivo stability.
Integrin αvβ3 is implicated in many disease processes—angiogenesis,
proliferation of vascular smooth muscle following injury, tumor metastasis,
inflammation, and osteolysis. With so many potential disease targets, it is an
interesting molecular target for diagnostic and therapeutic imaging. This work reports
on the investigation of structurally diverse bifunctional RGD peptides for affinity for
integrin αvβ3 in vitro and in vivo. In vitro characterization of RGD-functionalized
nanoparticles is also presented.
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CHAPTER 2

Preparation and In Vivo Investigation of 64Cu-Labeled Cross-Bridged
Tetrazamacrocyclic Complexes, C3B-DO2A and CB-TR2A: Comparison with NOTA

20

Abstract
Copper radionuclides have been the subject of considerable research effort
because they offer a varying range of half-lives and positron energies, making them
useful for diagnostic imaging and/or targeted radiotherapy. Ensuring the stability of
metal complexes in vivo remains a challenge in the development of radiometalbased radiopharmaceuticals. A new class of structurally reinforced macrocycles,
“cross-bridged” cyclam derivatives, form highly stable complexes with Cu(II) that are
resistant to dissociation in strong acid and have rapid tissue clearance in
biodistribution studies; however, their radiolabeling is inefficient and requires harsh
conditions that are unsuitable for larger biomolecules. Here, we report the evaluation
of three macrocyclic chelators--C3B-DO2A, CB-TR2A, and NOTA—as we seek more
rapid Cu(II) complexation kinetics while retaining the high in vivo stability of CBTE2A. The

nat

Cu complexes were characterized by structure evaluation, inertness to

acid decomplexation, and electrochemical properties. The inertness of Cu-C3BDO2A

to

decomplexation

is

remarkable,

exceeding

that

of

CB-TE2A.

Electrochemical reduction of Cu-CB-TR2A is quasi-reversible; Cu-C3B-DO2A and
Cu-NOTA are irreversible. The reaction conditions for preparing
(microwaving at high temperature) and

64

Cu-C3B-DO2A

64

Cu-CB-TR2A (basic ethanol) are relatively

harsh compared to those for the conventional complexes, such as DOTA. The in vivo
behavior of 64Cu-ligand complexes was evaluated in normal rats. Rapid and continual
clearance of

64

Cu-CB-TR2A and

64

Cu-NOTA through the blood, liver, and kidneys

suggests good in vivo stability, although inferior to

64

Cu-CB-TE2A. Although

64

Cu-

C3B-DO2A clears continually, the initial uptake is high and only about half is
excreted within 22 h, suggesting poor stability and transchelation of

64

Cu to proteins

in the blood and/or liver. These data suggest that in vitro stability of a chelator may
not always be a good indicator of in vivo stability. Furthermore, a macrocyclic
chelator with rapid complexation kinetics which also demonstrates kinetic inertness
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comparable to the previously studied

64

Cu-CB-TE2A, under physiological conditions,

has not yet been identified.

Introduction
Radiopharmaceuticals, drugs containing a radionuclide, are routinely used in
nuclear medicine for the diagnosis and therapy of various diseases.9,

53-55

An ideal

radiopharmaceutical would be injected intravenously, travel via the blood stream to
the target tissue or cells, and interact in an effective manner and with only the
desired molecular pathway.56 Excretion of any radiopharmaceutical that did not reach
the intended target would occur rapidly, leaving in the body only the fraction of the
radiotracer which localized to the target site. While an ideal compound may never
exist, the objective in radiopharmaceutical design is to come as close as possible.
Substrate-specific radiopharmaceuticals are designed to target a specific
biological process, protein, or receptor expressed in distinct regions of the body.
Generally, a substrate-specific metalloradiopharmaceutical is composed of four
parts: a targeting biomolecule, a linker, a bifunctional chelator (BFC), and a metallic
radionuclide (Figure 1).18, 57 Each of these components must be considered in light of
each other and optimized as a whole. Thus, the design of novel BFCs and their
characterization with specific radiometals is an area of ongoing research.
BFCs must form a very stable metal chelate, demonstrating kinetic inertness
at physiological pH. Its solution stability in biological medium depends primarily on a
slow rate of dissociation. This is important to avoid a loss of radiometal from the
chelate, resulting in the accumulation of radioactivity in non-target tissue that
obscures imaging of the desired target and increases the radiation dose the subject
receives. Rapid complexation kinetics are also favored to allow for easy formation of
the metal-chelator complex.
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Figure 1. Conceptual diagram of a substrate specific metalloradiopharmaceutical.

As discussed in the introduction (chapter 1), copper radionuclides have been
the subject of considerable research effort because they offer a varying range of halflives and positron energies, making them useful for diagnostic imaging and/or
targeted radiotherapy. Their half-lives range from 10 minutes to 62 hours, and they
decay by positron (β+) and/or beta-minus (β-) emission. The biodistribution of these
copper radionuclides can be assessed externally via clinical positron or gamma
imaging techniques. Copper-64 has a long history of applications as a biomedical
tracer because of its longer half-life and short positron range (T1/2=12.7 h; β+: 0.656
MeV, 17.8%; β-: 0.573 MeV, 38.45%).58
Kinetic stability of Cu(II) complexes has been shown to be more predictive of
in vivo stability than thermodynamic stability.22, 59 Since the coordination chemistry of
copper radionuclides has been extensively reviewed,15, 57 only a brief summary will
be given here. Macrocyclic chelators of Cu(II) such as TETA (1,4,8,11tetraazacyclotetradecane-1,4,8,11-tetraacetic acid) demonstrate higher kinetic and
thus in vivo stability relative to acyclic chelators such as EDTA (ethylene diamine
tetraacetic acid).12,

59, 60

However, biodistribution and metabolism studies of

TETA in rats have demonstrated significant transchelation of

64

Cu-

64

Cu to superoxide

dismutase and metallothionein in liver and albumin in blood resulting in high
background radioactivity.61,

62

Cu(II) complexes with a class of chelators called the
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cross-bridged

macrocycles,

in

particular

CB-TE2A

(4,11-bis(carboxymethyl)-

1,4,8,11-tetraazabicyclo[6.6.2]hexadecane), have shown much greater in vivo
stability;62,

63

however, a disadvantage of CB-TE2A is that labeling with copper

radionuclides requires heating to 95 ºC, and this precludes the use of this chelator
with proteins or other heat-sensitive compounds.

HOOC

COOH

N

N

HOOC

COOH

HOOC

DTPA

NH

HN

NH

HN

NH

HN

NH

HN

homocyclen

cyclen

HOOC

N

N

N

N

DOTA

COOH

COOH

COOH

HOOC

EDTA

HOOC

N

N

N

COOH

HOOC

COOH

HOOC

N

N

N

N

COOH

COOH

HOOC

N

N

N

N

COOH

CB-TE2A

TETA

Figure 2. Structures of representative polyamine and polyaminocarboxylate acyclic
and cyclic chelators for radiometal complexation.

To design cross-bridged chelators that complex Cu(II) with faster kinetics
while retaining the high in vivo stability of CB-TE2A, different ring sizes of crossbridged tetraazamacrocycles were designed. First, a dicarboxylate analog of
Springborg’s trimethylene-cross-bridged cyclen64,
analog,

65

was proposed. This DOTA

4,10-bis-(carboxymethyl)-1,4,7,10-tetrazazabicyclo[5.5.3]pentadecane
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(C3B-DO2A), has one more methylene unit in the cross-bridge than the previously
studied CB-DO2A.62 The biodistribution of

64

Cu-CB-DO2A demonstrated rapid

clearance of the agent through the blood, liver, and kidneys. It is hypothesized that
the increased ring size of C3B-DO2A will improve the radiolabeling kinetics while
retaining the in vivo stability of CB-DO2A.
Homocyclen has a ring size falling between that of cyclen and cyclam. Just
as C3B-DO2A was chosen for its slightly larger ring size than the previously studied
CB-DO2A, a two-carbon cross-bridged dicarboxylate analog of homocyclen, 4,11bis-(carboxymethyl)-(1,4,8,11-tetraazabicyclo[6.5.2]pentadecane

(CB-TR2A),

was

proposed.
Prasanphanich et al. recently reported

64

Cu-labeled bombesin analogs using

1,4,7-triazacyclononane-N,N’,N’’-triacetic acid (NOTA) as a chelator. The reduced
liver and intestinal accumulation suggested high in vivo kinetic stability of
NOTA-bombesin vectors with little or no dissociation of
chelator has been used multiple times as a BFC for

64/67

64

Cu-

64

Cu from NOTA.66 This

Cu and

68

Ga attachment to

antibodies67 and peptides68, 69; however, an evaluation of the in vivo stability of the
64

Cu-NOTA complex has not previously been reported. Stability constants for several

metal-NOTA complexes are found in literature70,
Cu(II)-NOTA and Ga(III)-NOTA.72,

73

71

as well as crystal structures for

NOTA deviates from most of the macrocyclic

chelators that we investigate because it is a triazamacrocycle and not cross-bridged;
however, its reported high in vivo stability and rapid labeling kinetics drive our
interest in this molecule.
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Figure 3. Structures of cross-bridged tetraazamacrocyclic chelators, C3B-DO2A and
CB-TR2A, as well as triazamacrocyclic chelator, NOTA.

Here we present the results of our efforts to develop kinetically stable crossbridged azamacrocycles. We synthesized a three-carbon cross-bridged DO2A, 4,10bis-(carboxymethyl)-1,4,7,10-tetrazazabicyclo[5.5.3]pentadecane (C3B-DO2A), and
a

two-carbon

cross-bridged

TR2A,

4,11-bis-(carboxymethyl)-(1,4,8,11-

tetraazabicyclo[6.5.2]pentadecane (CB-TR2A). These novel BFCs were investigated
for their potential use in constructing new PET imaging agents with improved
properties. Copper(II) complexes were synthesized and characterized by structure,
acid decomplexation and electrochemistry. Optimized

64

were established for each chelator. The biodistribution of

Cu-radiolabeling conditions
64

Cu-C3B-DO2A and

64

Cu-

CB-TR2A in normal rats was compared to another highly stable macrocyclic chelator
that

has

been

used

to

complex

64

Cu

to

biological

molecules,

1,4,7-

triazacyclononane-N,N’,N’’-triacetic acid (NOTA).

Experimental Procedures
Materials and methods. Unless otherwise specified all chemicals were
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) and used as received.
All solutions were prepared using water which had been distilled and then deionized
(18 MΩ/cm2) by passing through a Milli-Q water filtration system (Millipore Corp.,
Bedford, MA). Trace metals were removed from all buffers used for radiolabeling by
Chelex 100 resin (BioRad Laboratories, Hercules, CA). Whatman C18 silica gel TLC
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plates (KC18F, 60 Å, 200 µm) were purchased from Fisher Scientific (Pittsburgh,
PA). Copper-64 was prepared on a biomedical cyclotron at Washington University
Medical School by the

64

Ni(p,n)64Cu nuclear reaction at high specific activity as

previously described.74 Male Lewis rats were purchased from Charles River
Laboratories (Boston, MA).
Radio-TLC was accomplished using a Bioscan 200 imaging scanner
(Bioscan, Inc., Washington, DC). Analytical reversed-phase HPLC was performed on
a Waters 600E (Milford, MA) chromatography system with a Waters 991 photodiode
array detector and an Ortec Model 661 radioactivity detector (EG&G Instruments,
Oak Ridge, TN). Radioactive samples were counted with a Beckman 8000
automated well-type gamma counter (Beckman Instruments, Inc., Fullerton, CA) or a
Wallac Wizard 1480 automatic gamma counter (Perkin Elmer, Gaithersburg, MD).
Optimization of radiolabeling conditions for preparation of

64

Cu-C3B-

DO2A. A solution of C3B-DO2A (1 µg/µL) was prepared by dissolving the ligand in
0.1 M ammonium acetate, pH 7.0, or ethanol. Except for microwave assisted
reaction, all reactions were carried out in 1.5 mL acid washed conical vials and
shaken for the duration of the incubation. A variety of aqueous reaction conditions
were tested, with incubation times, ligand concentrations, buffer concentration and
pH, temperatures, and radiochemical yields reported in the results section (Tables 26). The method for radiolabeling described by Boswell et al. for the synthesis of 64CuCB-TE2A62, and described below for the production of

64

Cu-CB-TR2A, was tested for

formation of 64Cu-C3B-DO2A (Tables 7-8). At several time points, the outcome of the
labeling experiment was assessed by radio-TLC (Rf ~ 0.8, C18 silica plates, eluent:
methanol/10% ammonium acetate 7:3, Rf (64Cu-acetate = 0). Radio-TLC results for
some reactions were confirmed by radio-HPLC (Agilent C8 column; isocratic, 0.1%
formic acid in water; 0.5 mL/min). When radiolytic stabilizers were used, a final
concentration of 1 mM gentisic acid (GA) or ascorbic acid (AA) was added prior to
incubation. For carrier-added reactions, a 100 mM solution of CuCl2 in milliQ water or
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absolute EtOH was added to the ligand solution prior to addition of the

64

CuCl2.

Microwave assisted reactions were carried out using a Biotage Initiator closed vessel
reactor (Biotage AB, Uppsala, Sweden). Solvent, pH, temperature, and length of
reaction were varied to find conditions that resulted in consistent radiochemical purity
of ≥ 98% (Table 9).
The highest radiochemical purity with greatest consistency of yield was
obtained using a microwave assisted reaction. A solution of

64

CuCl2 (750 µCi in 50

µL milliQ water, pH 3) was added to 4.61 µg (14.0 nmol) C3B-DO2A dissolved in 250
µL of milliQ water (pH 3). The sealed vial containing the reaction mixture was placed
in the microwave reactor, stirred for two minutes, and then heated at 100 °C for 2 h.
Complex formation was confirmed by radio-TLC. Radiochemical purity was
determined by HPLC and found to be ≥ 98% before use in animal studies.
Preparation of

64

Cu-NOTA. An aqueous solution of

64

CuCl2 (1.3 mCi, 50 µL,

0.1 M NH4OAc, pH 7.0) was added to 4.17 µg (13.7 nmol) of NOTA dissolved in 50
µL of 0.1 M NH4OAc, pH 7.0. The reaction mixture was incubated with shaking at 37
°C for 1 h. Complex formation was followed by radio- TLC (Rf ~ 0.75, C18 silica
plates, eluent: methanol/10% ammonium acetate 7:3, Rf (64Cu-acetate = 0).
Radiochemical

purity

of

≥ 98% was attained.
Biodistribution Studies. Animal experiments were carried out in compliance
with the Guidelines for the Care and Use of Research Animals established by
Washington University’s Animal Studies Committee. Tissue distribution studies were
performed in male Lewis rats (34-42 day old) after intravenous injection of the
radiolabeled compound,
(100 µCi), or

64

Cu-C3B-DO2A (45 µCi; 0.9 nmol ligand),

64

Cu-CB-TR2A

64

Cu-NOTA (60 µCi; 0.5 nmol ligand), via the tail vein (100-150 µL).

Tissue biodistribution data were obtained at 1, 4, and 24 hours post injection (PI).
Animals were sacrificed at the appropriate time points, organs of interest were
removed and weighed, and the radioactivity was measured in a gamma counter. The
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percent injected dose per gram (%ID/g) and percent injected dose per organ
(%ID/organ) were calculated by comparison to a weighed and counted standard.
Rats were allowed food and water ad libitum. Animals in the 24 h group for
C3B-DO2A and

64

Cu-

64

Cu-NOTA were maintained in metabolism cages; urine and feces

were collected.
Statistical methods. All data are presented as the mean ± standard
deviation. Group comparisons were made using standard ANOVA methods. Post hoc
testing of individual group differences was accomplished with the Bonferroni test.
Groups with p < 0.05 were considered significantly different. GraphPad Prism
software (version 5.02; San Diego, CA) was used for all statistical analyses.
Collaborators. The experimental procedures for work performed by
collaborators are included as supplemental material Appendix I. Synthesis of C3BDO2A was performed by Dr. Riccardo Ferdani, CB-TR2A by Yijie Peng (University of
New Hampshire, Durham, NH)75 and NOTA by Elizabeth Garcia (UNH). Synthesis of
all
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Cu(II)-chelator complexes and their characterization was carried out at UNH in

the laboratory of Dr. Ed Wong. The Cu-CB-TR2A work has been reported in the
doctoral dissertation of Antoinette Odeendaal (UNH).76 X-ray crystallography was
done in the laboratory of Dr. Arnold Rheingold at the University of California—San
Diego (La Jolla, CA); Cu-CB-TR2A structure solved by James Golen. Dr. Thad
Wadas was responsible for radiochemistry involving CB-TR2A.

Results
Synthesis of Ligands. The synthesis and characterization of the chelator
and Cu(II) complex of the cyclen-based cross-bridged chelator, C3B-DO2A, and that
of the homocyclen-based cross-bridged chelator, CB-TR2A, have not previously
been reported. The low overall yield for the synthesis of C3B-DO2A (18%) was
primarily due to the cross-bridging step which had a yield of 21%. The compound
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has subsequently been synthesized by a different synthetic route in much higher
yield.
Cu-C3B-DO2A. The complexation of Cu(II) by the ligand was relatively slow,
requiring overnight reflux in 95% ethanol solution. It was found subsequently that
under microwave irradiation, the complex can be more conveniently formed in
aqueous solution at 85° after 1 h at pH 6. The comple x co-crystallized with NaClO4
as well as with waters of hydration. The solution electronic spectrum showed a
visible maximum at 614 nm, typical of Cu(II)-cross-bridged complexes. Solid-state
FT-IR spectrum revealed carboxylate bands at 1687 (m, s) and 1616 (s, bd) cm-1. An
X-ray structural determination of crystals grown from hexafluoro-i-propanol revealed
a distorted octahedral geometry with Jahn-Teller elongation along one N-Cu-O axis
(Figure 4). The cation is only slightly distended from the chelator cavity with an
“axial” N-Cu-N angle of 173.6° and “equatorial” N-C u-N angle of 97.5°.
The inertness of Cu-C3B-DO2A (half-life = 7.2(7) days) to decomplexation in
12M HCl at 90 °C, even exceeding that of the Cu-CB-T E2A (half-life = 1.3(2) h)57, is
remarkable. This attests to the optimal envelopment of the Cu(II) within the ligand’s
hexadentate coordination sphere. To begin the demetallation process, dislodgement
of at least one pendant arm and rupture of a Cu-N bond must be followed by major
chelator structural rearrangements. The kinetic barrier to such an event must be
significantly higher even than that for Cu-CB-TE2A, previously the most acid-inert
Cu(II)-tetraazamacrocyclic complex.
Similar inertness is not observed upon electrochemical reduction as revealed
by the cyclic voltammogram of this complex. An irreversible reduction was found
near -1.0 V (Ag/AgCl) with no reoxidation peak until the large stripping peak near 0
V, indicative of copper metal deposition. Thus Cu(I)-C3B-DO2A, if formed, must have
low stability in aqueous solution and is thus rapidly demetallated.
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Figure 4. Structures of Cu-C3B-DO2A and Cu-CB-TR2A (Complex A) based on
crystallographic data. For clarity, all hydrogens are omitted.
Cu-CB-TR2A. The complexation of Cu(II) by the ligand CB-TR2A was
accomplished following overnight reflux in 95% ethanol solution. Elemental analysis
of

Cu-CB-TR2A

was

consistent

with

a

composition

of

Cu•CB-

TR2A•1.2Na(ClO4)•2H2O. Two strong broad IR bands were observed, one at 1610
cm-1, which corresponds to the carboxylate stretching vibration, and another at 1098
cm-1, which corresponds to the perchlorate stretching vibration. The UV-Vis spectrum
in H2O has an absorption λmax at 608 nm (ε = 32.1 M-1cm-1).
An X-ray crystal structure determination of Cu•CB-TR2A was obtained after a
second slow Et2O diffusion into a solution of complex in 95% EtOH. The structure
showed the presence of three unique cis-V-folded complexes each with a sixcoordinated distorted octahedral copper, but each with a different ligand
conformation (Complex A shown in Figure 4). Jahn-Teller elongated bonds were
observed for each complex along one N-Cu-O axis. The metal center is only slightly
distended from the chelator cavity as indicated by the “axial” N-Cu-N bond angles
(Complex A: “axial” N-Cu-N 176.8(2)o; Complex B: 168.7(2)o).
The acid-decomplexation half-life of Cu-CB-TR2A was determined to be
10.8(4) h in 5 M HCl at 30 oC, conducted under pseudo-first order conditions. This is
between the half-lives of Cu-CB-DO2A and Cu-CB-TE2A (Table 1). Although not as
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kinetically inert as Cu-CB-TE2A, Cu-CB-TR2A is significantly more resistant to acid
decomplexation than Cu-CB-DO2A whose ligand cavity is smaller. The cyclic
voltammogram of Cu-CB-TR2A has a quasi-reversible reduction at -0.95 V (vs.
Ag/AgCl) with a peak separation of 138 mV. This is between the values found for CuCB-TE2A and Cu-CB-DO2A (Table 1) and indicates that Cu-CB-TR2A is more
resistant to reductive demetallation than Cu-CB-DO2A, though not as resistant as
Cu-CB-TE2A. Quasi-reversible reduction suggests that the chelator can adapt a
geometry suitable for Cu(I) coordination.77

Table 1. Pseudo first-order half-lives for acid-decomplexation and
reduction potentials of copper(II) complexes.
Complex
Cu-C3B-DO2A

12 M HCl,
90°C
7.2(7)
days

5 M HCl,
90°C

5 M HCl,
30°C

Ered (V) vs.
Ag/AgCl

Overall
Charge

nd

nd

-1.03 (irrev)

0

Cu-CB-DO2Ab

nd

nd

< 2 min

-0.85 (irrev)

0

Cu-DOTA

< 3 mina

nd

nd

-0.94 (irrev)c

-2

-0.95 (quasirev, ∆E=138
mV)
-1.08 (quasirev, ∆E=120
mV)

Cu-CB-TR2A

nd

nd

10.8(4) h

Cu-CB-TE2Aa

1.6(2) h

154(6) h

> 1 year

Cu-TETAb

< 3 min

4.5(5) min

3.5(2) days

-1.18 (irrev)

+2

Cu-cyclama

< 3 min

< 3 min

nd

-0.68 (quasirev)

+2

Cu-NOTA

nd

nd

< 3 min

-0.9, -1.2 (irrev)

-1

57

0

0

77

Previously published data: a=Wadas et al. ; b=Woodin et al. ; c=Boswell et al.62

Cu-NOTA. The acid inertness of this complex in 1M HCl at 30 °C is superior
to that of Cu-cyclen, Cu-TACN, and Cu-CB-DO2A, all of which were completely
decomplexed after 1 day. It is, however, demetallated within minutes in 5 M HCl at
30 °C, making it considerably less inert than Cu-DOTA, Cu-TETA, as well as Cu-CBTR2A (Table 1). Among the chelators shown here, Cu-C3B-DO2A is the most
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kinetically inert and Cu-NOTA one of the least. The relative order is Cu-C3B-DO2A >
CB-TE2A >> Cu-TETA ≈ Cu-DOTA > Cu-CB-TR2A > Cu-CB-DO2A ≈ Cu-NOTA.
While they only provide a qualitative estimate of comparative kinetic inertness, the
resistance of a copper chelate complex to aqueous acid decomplexation generally
serves as a useful first indicator of the likely in vivo integrity of the complex towards
metal loss due to protonation, competing biometals, or biological ligands.78
The cyclic voltammogram contained two irreversible reduction peaks at -0.9
and -1.2 V (Ag/AgCl) along with the large copper stripping peak upon reoxidation.
Thus Cu(I)-NOTA does not appear to be a stable species in aqueous solution.
Comparison to other chelators is provided in Table 1. A threshold potential of
approximately -1 V with quasi-reversibility is generally indicative of good in vivo
stability.
Radiochemistry. Optimization of the radiolabeling conditions for

64

Cu-C3B-

DO2A to be compatible with the conjugation and labeling of proteins (i.e. lower
temperature) was not attained. Radiolabeling was attempted under a variety of
aqueous conditions varying the buffer, pH, and temperature. The reaction conditions
and

64

Cu-labeling yields for numerous attempts to attain rapid kinetics in aqueous

ammonium acetate (NH4OAc) are presented in Tables 2-4. For reaction conditions
repeated multiple times, the highest yield is reported in each series.
Phosphate and citrate buffers resulted in similarly inconsistent and
disappointing yields (Table 5). Reactions were monitored over time to assess the
rate of complexation. Instability of the

64

Cu-C3B-DO2A complex was observed in the

form of secondary peak formation and yields which peaked and then declined.
Although radiolysis is not commonly observed for small molecules, reactions were
carried out in the presence of two different radiolytic scavengers (Table 6). Carrieradded reactions did not produce any improvement in radiolabeling.
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Table 2. Initial radiolabeling attempts for 64Cu-C3B-DO2A. In all reactions
0.5 µg C3B-DO2A was incubated with 100 µCi 64Cu in a total volume of 50 µL.
Yield (%)
Temp
Buffer
Concentration
pH
(°C)
30 m
7h
NH4OAc
0.1 M
8.0
25
6
9
NH4OAc
0.5 M
6.0
25
6
28
NH4OAc
0.5 M
8.0
25
23
52
NH4OAc
1.0 M
7.0
25
4
22
1.25 M
4.5
25
1
3
NH4OAc
NH4OAc
0.1 M
8.0
37
3
9
NH4OAc
0.5 M
6.0
37
11
9
0.5 M
8.0
37
23
12
NH4OAc
NH4OAc
1.0 M
7.0
37
1
10
NH4OAc
1.25 M
4.5
37
1
2

Table 3. Secondary radiolabeling attempts for 64Cu-C3B-DO2A. In all reactions
1.0 µg C3B-DO2A was incubated with 100 µCi 64Cu in 0.1 M NH4OAc (50 µL).
Yield (%)
pH
Temp (°C)
1.5 h
3.5 h
18 h
6.0
25
47
45
32
7.0
25
27
46
82
8.0
25
72
45
40
6.0
95
30
58
90
7.0
95
19
19
35
8.0
95
34
50
90

Table 4. Further radiolabeling attempts for 64Cu-C3B-DO2A. In all reactions
1.0 µg C3B-DO2A was incubated with 150 µCi 64Cu in 0.1 M NH4OAc (50 µL).
Yield (%)
Temp
1h
6h
pH
(°C)
8h
18 h
8
25
6
8
14
54
8.5
25
8
31
43
21
9
25
11
36
56
41
8
40
4
22
7
39
8.5
40
40
12
10
32
9
40
69
5
83
13
8
95
27
53
49
46
8.5
95
26
49
37
68
9
95
21
53
66
79
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Table 5. Alternate buffers used for attempted radiolabeling of 64Cu-C3B-DO2A.
In all reactions 0.5 µg C3B-DO2A was incubated with 70 µCi 64Cu in a total
volume of 50 µL at 95 °C.
Yield (%)
Buffer
Concentration
pH
1h
4h
NH4Citrate
0.1 M
5.5
21
23
NH4Citrate
0.1 M
7.0
31
30
NH4Citrate
0.1 M
8.0
64
58
0.5 M
7.0
28
39
NH4Citrate
Na2PO4
0.1 M
5.5
34
18
Na2PO4
0.1 M
7.0
22
55
0.5 M
7.5
27
51
Na2PO4

Table 6. Radiolabeling attempts for 64Cu-C3B-DO2A with radiolytic
scavengers. In all reactions 1.0 µg C3B-DO2A was incubated with
100 µCi 64Cu in 0.1 M NH4OAc (50 µL) at 95 °C.
Yield (%)
pH
Scavenger
1h
4h
16 h
5.5
GA
7
20
33
7
GA
8
45
64
8.5
GA
21
34
61
5.5
AA
5
11
22
7
AA
17
45
42
8.5
AA
32
36
62

After such exhaustive attempts at radiolabeling under aqueous conditions,
the standard CB-TE2A radiolabeling conditions79 were attempted (Tables 7-8). Table
7 includes data on a radiolabeling attempt using Li2CO3 as the base instead of
Cs2CO3. The effect of specific activity was assessed showing limited improvement in
radiochemical yield (Table 8). Again, carrier-added reactions did not generate any
improvement in radiolabeling yield.
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Table 7. Radiolabeling 64Cu-C3B-DO2A in ethanol with excess base.
In all reactions 0.5 µg C3B-DO2A was incubated with 100 µCi 64Cu.
Yield (%)
Time
Cs2CO3; 100 µL
Cs2CO3; 50 µL
Li2CO3; 100 µL
1h
43
70
3
3h
60
43
5
4.5 h
70
nd
4
6h
65
nd
3
35
nd
6
18 h

Table 8. Radiolabeling 64Cu-C3B-DO2A in ethanol with excess Cs2CO3.
In all reactions C3B-DO2A was incubated with 130 µCi 64Cu in a total volume of 80
µL.
Yield (%)
3 µg C3BTime
1 µg C3B-DO2A 2 µg C3B-DO2A
DO2A
1h
32
64
64
2.5 h
37
67
85
4h
32
63
83
6h
20
47
nd
30
66
74
18 h

In an attempt to speed up the reaction kinetics, the use of a microwave
reactor was employed (Table 9). While reaction times can be shortened due to the
concentrated heating of a microwave reactor, the sealed vial system limited the
number of time points assessed for each set of reaction conditions. Shorter reaction
times did not initially produce high yields, so longer reaction times were utilized until
higher yields were attained. Then reaction length optimization occurred, finding the
shortest reaction time required to consistently provide a minimum of 97%
radiochemical purity.
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Table 9. Microwave assisted radiolabeling 64Cu-C3B-DO2A. In all reactions 1.0 µg
C3B-DO2A was incubated with ~100 µCi 64Cu in a total volume of 300 µL.
Solvent
pH
Temp (°C)
Time
Yield (%)
0.1 M NH4OAc
7
60
1h
9
0.1 M NH4OAc
7
60
4h
30
0.1 M NH4OAc
7
95
1h
38
0.1 M NH4OAc
7
95
4h
50
0.1 M NH4OAc
7
95
6h
28
0.5 M NH4OAc
7
60
1h
38
0.5 M NH4OAc
7
85
4h
44
0.5 M NH4OAc
7
95
1h
39
0.5 M NH4OAc
7
95
4h
55
0.1 M NH4OAc
5
95
4h
61
0.1 M NH4OAc
8.5
95
4h
82
0.1 M NH4OAc
8.5
150
4h
48
0.1 M NH4OAc
8.5
180
4h
45
0.1 M Na2PO4
7
60
4h
39
0.1 M Na2PO4
7
95
4h
59
0.5 M Na2PO4
7.5
95
4h
52
milliQ water
3
95
4h
87
milliQ water
3
100
4h
99
milliQ water
3
100
1h
91
milliQ water
6
95
4h
83
milliQ water
6
100
4h
94
milliQ water
6
100
1h
85
milliQ water
3
100
2h
99
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CB-TR2A was successfully labeled with
CB-TE2A and other cross-bridged chelators24,

64

Cu by the method employed for

79

(radiochemical purity ≥ 98%) at

room temperature in basic ethanolic solution. A single peak corresponding to

64

Cu-

CB-TR2A was confirmed by radio-TLC.
The NOTA chelator used for comparison was successfully labeled with

64

Cu

at room temperature in neutral buffer solution, with radiochemical purity ≥ 98%
attainable within one hour. A single peak corresponding to

64

Cu-NOTA was verified

by radio-TLC.
Biodistribution Studies. The biodistribution of
TR2A, and

64

Cu-C3B-DO2A,

64

Cu-CB-

64

Cu-NOTA were determined in normal, juvenile Lewis rats to examine

their in vivo properties. The blood, liver, and kidney clearance of these agents are
64

Cu-CB-DO2A62 and

plotted in Figure 5 along with previously published data of
64

Cu-CB-TE2A63 for comparison. For 64Cu-CB-TR2A and 64Cu-NOTA rapid clearance

of the agent through the blood, liver, and kidneys was observed, suggesting that the
intact complex is clearing because dissociated

64

Cu binds to proteins and remains

trapped in tissues, hindering clearance.61 Comparable levels of clearance are
64

observed for blood (%ID/g at 24 h PI:

Cu-CB-TR2A, 0.010±0.002;

0.016±0.001) and liver (%ID/g at 24 h PI:

64

Cu-CB-TR2A, 0.075±0.014;

64

Cu-NOTA,

64

Cu-NOTA,

0.086±0.009). The highest uptake in all organs is observed for 64Cu-C3B-DO2A at all
time points. Clearance of

64

Cu-C3B-DO2A is slow but continuous (from 1h to 22 h:

blood 29.8% reduction; liver 22.2%; kidney 50.4%). All other compounds have higher
64

percent reduction for all three organs than

Cu-C3B-DO2A. The rate of clearance

from liver is higher for cyclam-based cross bridged chelators and lower for noncross-bridged NOTA (percent reduction at 22 or 24 h PI:
64

Cu-NOTA, 46.3%;

64

Cu-C3B-DO2A, 22.2%;

64

Cu-CB-TR2A, 66.4%;

64

Cu-CB-DO2A, 69.5%;

64

Cu-CB-

TE2A, 90.2%). Kidney uptake cleared by at least 50% for all complexes (percent
reduction at 22 or 24 h PI:
DO2A, 50.4%;

64

64

Cu-CB-TR2A, 89.2%;

Cu-CB-DO2A, 95.6%;

64
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64

Cu-NOTA, 80.1%;

64

Cu-C3B-

Cu-CB-TE2A, 99.1%). This results in

excretion of the complexes in the urine (Table 10). Excluding

64

Cu-C3B-DO2A, the

highest levels of 64Cu remaining in the blood and tissues at 24 h is observed for 64CuNOTA as well as the lowest percent reduction from 1 to 24 h. These data
demonstrate that the

64

Cu-labeled cross-bridged chelates are cleared more

completely from the blood, liver, and kidneys than the non-cross-bridged analogues,
with

64

Cu-CB-TE2A having the lowest amount of

tissues after 24 h.62
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64

Cu remaining in the blood and

Figure 5. Selected organ biodistribution for

64

Cu-C3B-DO2A,

64

Cu-NOTA. Plotted with previously published data for

64

Cu-CB-TR2A, and

64

Cu-CB-DO2A62 and

63

CB-TE2A for comparison. Note differences in scale.

Table 10. Excretion data for 64Cu-C3B-DO2A and 64Cu-NOTA, 0 - 24 h PI.
% ID
Complex

Urine

Feces

64

46.0 ± 5.2

5.4 ± 1.2

64

74.9 ± 7.1

4.4 ± 4.9

Cu-C3B-DO2A
Cu-NOTA
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64

Cu-

Discussion
It was initially proposed that cross-bridged chelators would form more stable
complexes with copper radionuclides thereby improving pharmacokinetics of

64

Cu-

labeled cross-bridged ligand biomolecule conjugated for enhanced imaging.
Research has confirmed this hypothesis, demonstrating superior kinetic and in vivo
stability of these chelators as carriers for copper radionuclides compared to
traditional macrocyclic ligands.22, 62, 63 Greater kinetic stability improved target uptake
and pharmacokinetics of cross-bridged ligand-peptide conjugates for molecular
imaging purposes.25 In this work we investigated a second generation of crossbridged macrocyclic chelators of copper-based radiopharmaceuticals for imaging of
cancer and other diseases. Pendant-armed cross-bridged cyclen and homocyclen
derivatives were designed taking into consideration the convenience of synthetic
routes, radiometal binding ability, and rapid complexation kinetics to enable efficient
radiolabeling of proteins under mild conditions. The kinetic and thermodynamic
properties of the coordination complexes were studied and correlation between these
properties and desired in vivo behavior was examined.
Comparison of the crystal structures of Cu(II)-C3B-DO2A and Cu(II)-CBTR2A reveals strong similarities in the coordination geometry of these complexes.
Both have cis-coordinating O’s with Jahn-Teller distortion along the N-Cu-O bond.
This is consistent with previously published structures of Cu(II)-CB-TE2A and Cu(II)CB-DO2A.23,

62

Both Cu(II)-C3B-DO2A and Cu(II)-CB-TR2A are slightly “exo,”

meaning that the metal protrudes from the ligand cleft, revealing the poor fit of the
metal in the complex. The Cu(II)-CB-DO2A structure also reveals a protrusion of the
Cu(II) from the ligand cleft.62 Cu(II)-CB-TE2A, however, has been shown to have a
less pronounced Jahn-Teller distortion, and the copper cation fits snuggly in the cleft
of the cross-bridged chelator.77 Stable coordination conformation, including how well
the metal fits in the chelator, contributes to good in vivo stability.
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In vitro inertness of copper chelators has been investigated as a convenient
indicator

of

in

vivo

stability.

Aqueous

acid-assisted

decomplexation

of

polyazamacrocyclic copper complexes is a known indicator of their kinetic
inertness.77 Comparison of the decomplexation half-lives suggested that Cu-C3BDO2A should be more stable than Cu-CB-TR2A in vivo although the biodistribution
study did not confirm this. The acid decomplexation mechanism has not yet been
elucidated, so the data should be interpreted with caution.
The coordination preferences for Cu(II) and Cu(I) are significantly different,
thus in vivo reduction of stable Cu(II) complexes to form Cu(I) products can lead to
demetallation and transchellation to a variety of copper-binding biomolecules. The
quasi-reversibility of Cu(II)-CB-TR2A compared to Cu(II)-CB-DO2A’s irreversible
reduction, likely contributes to its superior in vivo behavior, relatively speaking. A
quasi-reversible reduction was also reported for Cu-CB-TE2A.77 The quasireversibility demonstrated by Cu-CB-TR2A suggests that, like CB-TE2A, the ligand is
capable of adapting to a geometry suitable for Cu(I) coordination.57 The quasireversibility is thought to stem from the ability of the molecule to adjust somewhat to
the tetrahedral geometry favored by Cu(I).80 This malleability on the part of the
chelator enhances the stability of the chelator in vivo, providing resistance to metal
loss from the chelator upon reduction.
The reaction conditions for preparing
temperature) and

64

Cu-C3B-DO2A (microwaving at high

64

Cu-CB-TR2A (basic ethanol) are relatively harsh compared to

those for the conventional complexes, such as DOTA. NOTA, however, is easily
radiolabeled with 64Cu using conditions compatible with protein conjugation (aqueous
media at temperatures below 43 °C). The need for ha rsh radiolabeling conditions to
form the complex is not indicative of complex stability in vivo. However, a positive
correlation between the harshness of the conditions required for complex formation
and the acid-decomplexation half-life has been observed.
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Evaluation of the biodistributions of the ligands shows rapid clearance of
64

Cu-CB-TR2A and 64Cu-NOTA through the blood, liver, and kidneys, consistent with

what has been previously reported for

64

Cu-labeled azamacrocyclic complexes.22, 62

The initial high uptake and slow clearance of
stability and transchelation of

64

studies.61,

64

81

Biodistribution of

64

Cu-C3B-DO2A suggests poor in vivo

Cu to proteins, as has been observed in previous

Cu-NOTA showed similar trends to

64

Cu-CB-TR2A

and CB-TE2A, but demonstrated a lower rate of clearance from liver and blood within
24 h compared to the 64Cu-labeled cross-bridged complexes.
Many parameters control the behavior of radiopharmaceuticals in biological
media, and some of them cannot be easily predicted requiring in vivo studies. CB64

TE2A remains the best cross-bridged chelator for

Cu and other copper

radionuclides. Beyond the favorable in vitro characterization77, in vivo clearance and
metabolism studies indicate the enhanced stability of

64

Cu-CB-TE2A.62 The in vivo

stability of Cu(II)-C3B-DO2A and Cu(II)-CB-TR2A complexes could be further
evaluated by examination of the radiometabolites and determination of the extent of
transchelation to proteins.
Previous work correlated acid stability and resistance to electrochemical
reduction in aqueous conditions to biodistribution in normal rats, showing that
biological stability might be predicted by thresholds of acid stability and reduction
potentials.59, 77 While this does not hold for all of the compounds presented here, the
in vitro characterization of BFCs remains a valuable tool for understanding the
multifaceted in vivo biodistribution, stability, and metabolism of radiopharmaceuticals.
A macrocyclic chelator with rapid complexation kinetics which also demonstrates
kinetic inertness comparable to the previously studied

64

Cu-CB-TE2A under

physiological conditions has not yet been identified. Further research in developing
Cu(II) chelators with even greater stability is clearly warranted.
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CHAPTER 3

In Vitro and In Vivo Investigation of Structurally Diverse
64

Cu-Labeled RGD Peptides for PET Imaging of αvβ3 Expression
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Abstract
Integrin αvβ3 is upregulated in tumor vasculature, osteoclasts and areas of
collateral circulation following ischemic injury. Here, we investigate structurally
diverse bifunctional RGD (Arginine-Glycine-Aspartic acid) peptides for αvβ3 integrin
affinity in vitro and in vivo. A series of peptides containing the RGD sequence were
synthesized. Affinity to αvβ3 and specificity against αvβ5 and αIIbβ3 were determined in
an isolated, competitive binding assay for the peptide alone and several peptide
conjugates. A lactam-cyclized peptide (c(RGDyK)) demonstrated higher affinity for
αvβ3 than disulfide-cyclized (KCRGDC) or linear peptide (GRGDS). Disulfide-cyclized
peptides exhibited the best selectivity of the ligands investigated. A control, lactamcyclized peptide (c(RADyK)) has low affinity for all three integrins. Conjugation of
Cu(II)-containing chelators did not affect the binding affinity or selectivity of the
peptides. Cellular uptake studies in an αvβ3-positive cell line (U87MG human
glioblastoma cells) were performed using four different 64Cu-DOTA-labeled peptides.
In cell studies the disulfide-cyclized peptide showed the greatest amount of
internalization. Uptake of RGD peptides could be blocked by high doses of unlabeled
peptide. Internalization of the control peptide was minimal although receptormediated surface binding was observed. Disulfide-linked KCRGDC exhibited the
best in vitro behavior. Biodistribution studies in U87MG tumor-bearing nu/nu mice
showed rapid uptake and retention of the 64Cu-labeled peptides in tumor with good
tumor:blood and tumor:muscle ratios. At 4 h post-injection tumor:muscle ratios for all
three compounds were similar, but 64Cu-DOTA-c(RGDyK) has a significantly higher
tumor:blood ratio (p< 0.001). Uptake of 64Cu-DOTA-c(RGDyK) can be blocked by coadministration of high doses of unlabeled peptide. Blocking of 64Cu-DOTA-KCRGDC
and 64Cu-DOTA-GGRGDS uptake at 1 h was not attained with either co-injection or
pre-injection (15 min or 1 h) of cold peptide. Small-animal PET/CT imaging of 64CuDOTA-KCRGDC and 64Cu-DOTA-GGRGDS afforded visualization of the tumor,
consistent with the biodistribution profiles. There was no observed difference
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between block and non-block uptake (SUV at 4 h PI: 64Cu-DOTA-KCRGDC,
0.79±0.17; 64Cu-DOTA-KCRGDC + block, 0.98±0.36; 64Cu-DOTA-GGRGDS,
1.45±0.23; 64Cu-DOTA-GGRGDS + block, 1.58±0.075). Further in vivo investigation
is warranted to demonstrate targeting specificity of the peptides along with
investigation of a different peptide as a control. Higher binding affinity is being
investigated through multimeric peptides and conjugation of several peptides onto
the surface of nanoparticles.

Introduction
Cell-cell and cell-matrix interactions play an important role in tumor
metastasis and are essential during three specific processes: 1) dissociation of
individual cells from the primary tumor and invasion of the adjacent tissue; 2)
adherence in the capillary bed of the target organ; and 3) extravasation and arrest in
the foreign tissue (Figure 1).82,

83

Integrins comprise one class of cell surface

receptors participating in these cell adhesion processes. They are heterodimeric,
transmembrane receptors composed of an α- and a β-subunit.28 There are 24 known
mammalian heterodimer pairs arising from combinations of the 18 known α-subunits
and 8 β-subunits. Among the most interesting members of the integrin family are
αIIbβ3, also known as glycoprotein IIb/IIIa, which is involved in platelet aggregation,84
and αvβ3, the vitronectin receptor.
Integrin αvβ3 is expressed in a variety of cell types including endothelial
cells85, platelets86, osteoclasts38,

87

, melanoma, and smooth muscle cells.30 This

receptor is known to be over-expressed on many tumor cells, such as
osteosarcomas, neuroblastomas, glioblastomas, breast, prostate, and invasive
melanomas.31,

88, 89

Additionally, αvβ3 has been shown to be important during

angiogenesis, tumor-induced and otherwise (Figure 1).90 Consequently, many
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researchers are searching for high affinity, selective αvβ3 antagonists for diagnostic
and therapeutic applications.91

Figure 1. Targets for tumor imaging based on αvβ3-tageting tracers, such as labeled
RGD peptides. Integrin αvβ3 is highly expressed on metastatic tumors and on
endothelial cells undergoing angiogenesis. (Reprinted with permission from R.
Haubner.83)

The amino acid sequence arginine-glycine-aspartic acid (RGD) is common to
various extracellular matrix (ECM) proteins involved in cell-matrix adhesion, e.g.
vitronectin, fibronectin, fibrinogen, thrombospondin, and von Willebrand factor.92
Molecular interaction between these ECM proteins and integrins are known to
mediate many biological processes.93 The RGD-binding site is involved in cell
morphology, differentiation, proliferation, and gene expression.94 Many linear and
cyclic peptides incorporating the RGD sequence have been developed to take
advantage of these properties.95
The most prominent lead compound for development of radiotracers for noninvasive determination of αvβ3 expression is the lactam-cyclized pentapeptide,
cyclo(Arg-Gly-Asp-D-Phe-Val), which demonstrates high affinity for αvβ3.96 The first
evaluation of this approach involved radioiodination of a series of RGD peptides.97-99

47

In vitro assays showed comparable affinity for αvβ3 and selectivity against αIIbβ3 as
the lead structure. Receptor-specific tumor uptake was observed in vivo in nude mice
bearing tumor xenografts of human melanoma (M21) and mammary carcinoma
(MaCaF).

Predominantly

hepatobiliary

clearance

resulted

in

high

activity

concentration in liver and intestine. Strategies to improve pharmacokinetics of
radiohalogenated peptides have been undertaken.
Glycosylation improved pharmacokinetics and increased activity uptake and
retention in the tumor compared to the first-generation peptides.100 Conjugation of
hydrophilic D-amino acids shifted elimination to the renal pathway.101,

102

However,

tumor uptake was lower than observed with the glycosylated peptides. PEGylation is
known to improve plasma stability, immunogenicity, and pharmacokinetics of
peptides and proteins.74 Chen, et al. systematically studied the effects of various
PEG moieties on radioiodinated103, F-18104, and Cu-64-labeled105 derivatives. The
studies showed different effects of PEGylation on the pharmacokinetics, while tumor
uptake and retention of RGD-peptides was dependent on the nature of the lead
compound and minimally on the size of the PEG moiety.
Besides radiohalogenation, a variety of radiometal-based RGD tracers have
been developed. Typically the ε-amino function of the lysine in the lead structure
cyclo(Arg-Gly-Asp-D-Xaa-Val), where Xaa is Phe or Tyr, is conjugated with a
111

chelating moiety. Van Hagen et al. coupled c(RGDyK) with DTPA for

In labeling

and demonstrated αvβ3 specific binding in newly formed vessels by autoradiography
using human tumor tissue sections.96 Conjugation of the cystein-containing
tetrapeptide sequence H-Asp-Lys-Cys-Lys-OH or macrocyclic chelator DOTA to
cyclo(Arg-Gly-Asp-D-Phe-Lys) allowed for the preparation of

99m

Tc-,

188

Re- and

90

Y-

labeled analogues.106 All of these compounds exhibit high receptor affinity and
selectivity as well as specific tumor accumulation. However, the pharmacokinetics of
most of them need improvement.
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Phage display has generated additional RGD derivatives. RGD-4C ((Cys2Cys10, Cys4-Cys8)H-Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-OH) contains
two disulfide bridges and binds with moderate affinity to both αvβ3 and αvβ5.107 A
shortened derivative of RGD-4C coupled with HYNIC and labeled with

99m

Tc was

found to have only marginal tumor uptake which can be explained by the modest
αvβ3 binding affinity.108,
acids, or labeling with

109

99m

Conjugation with HYNIC, deletion of the terminal amino

Tc impairs the affinity to integrin αvβ3 resulting in a peptide

not suitable for in vivo imaging.
Apart from the cyclic structures, a few linear peptides have been investigated.
Using a new labeling strategy allowing for 18F-labeling of peptides on a solid support,
4-[18F]fluorobenzyl-Lys-Pro-Gln-Val-Thr-Arg-Gly-Asp-Val-Phe-Phe-Glu-Gly-NH2 was
synthesized.110 Despite exhibiting high αvβ3 binding affinity, biodistribution studies
and PET images showed low activity accumulation in the tumor. Analysis of blood
and urine samples revealed no intact peptide present as soon as 5 min postinjection, indicating that the linear peptide is metabolically unstable. A linear
decapeptide (Arg-Gly-Asp-Ser-Cys-Arg-Gly-Asp-Ser-Tyr) containing two RGD sites
and labeled with

99m

Tc via the Cys5 within the peptide was studied in 14 patients with

melanoma.111 Despite a fast renal clearance rate, the peptide localized to most
metastatic

melanoma lesions

with

specific

tumor

accumulation.

Tumor-to-

background ratios were generally low due to high lung and abdomen background
activity levels. Some small linear peptides, e.g. GRGDSPK, are reported to have low
selectivity for distinct integrin subtypes, but the affinity and selectivity of such tracers
has not been described thus far.112, 113
Multimeric compounds presenting more than one RGD site have been
introduced. Janseen et al. synthesized a dimeric peptide by coupling two cyclo(ArgGly-Asp-D-Phe-Lys) units via a glutamic acid linker with DOTA or HYNIC conjugated
to the free amino function of the linker moiety for radiolabeling.114,

115

Technetium-

99m-HYNIC-E-[c(RGDfK)]2 exhibited a 10-fold higher affinity for αvβ3 than the
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monomeric

99m

Tc-HYNIC-c(RGDfK). The groups of Kessler and Wester carried out a

systematic study on the influence of multimerization on receptor affinity and tumor
uptake.116,

117

A PEG linker and lysine moieties connected different numbers of

c(RGDfE) peptides. An in vitro binding affinity assay and PET images show
increasing affinity in the series monomer, dimer, tetramer, and octamer. Many other
groups have had varying degrees of success with multimerization.118-121 Overall,
multimerization leads to increased binding affinity and tumor uptake as well as
retention. Through the use of appropriate linker moieties, the pharmacokinetics of the
peptide-based tracer can be improved.
A

wide

variety

of

non-peptide

low

molecular

weight

compounds

(petidomimetics) have been developed based on structure-activity investigations in
the past decade. These will not be reported upon here, but they have been
extensively reviewed elsewhere.122-127
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Figure 2. The standard RGD sequence in comparison with high affinity ligands for
integrin αvβ3. (A) A schematic representation of the RGD binding motif. Specificity
and affinity for αvβ3 has been introduced in peptide ligands by ring closure and
flanking amino acids, which force the arginine and aspartic acid side-chains into the
proper conformation. In RGD-mimetics, the two domains that interact with the
integrin (Arg and Asp) have been replaced by a guanidine binding site and
carboxylate group. (B) Structures of c(RGDf(N-Me)V), RGD4C, and the quinolone
vitronectin receptor antagonist SH066 described by Harris et al.128 All are high affinity
ligands for αvβ3. (Figure adapted from Temming et al.129)
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As mentioned above, most of the integrin super-family members recognize
the RGD tripeptide sequence, an epitope shared by a variety of extracellular ligands.
Structural similarities within the integrin family and between their respective ligands
make selectivity a major concern in the design of potential diagnostic imaging and
therapeutic agents.130 The affinity of RGD peptides for their ligands may be affected
by steric conformation of the peptide.131-133 The RGD sequence assumes very
different conformations in different proteins, which have similar affinities to cell
attachment134,

135

and disintegrins.136-138 The RGD sequences of these proteins are

almost always located in flexible loop regions. Amino acids flanking RGD have also
been suggested to affect the selectivity and affinity of peptides toward integrins.139, 140
In addition to direct interactions between these residues and the integrin, flanking
groups influence the folding of the peptide and the conformational features of the
RGD-motif. Cyclization is commonly employed to improve the binding properties of
RGD peptides. By conferring rigidity to structure, it improves the selectivity of the
“promiscuous” RGD-sequence for a specific integrin sub-type.129 Systematic
substitution studies have shown that the positive and negative charges of the
argenine (R) and aspartic acid (D) side chain functionalities and the unmodified
glycine (G) spacer residue are critical.141, 142 Most RGD peptidomimetics studied as
αvβ3 antagonists share a common pattern, consisting of a rigid, preferably achiral
core unit, which links a guanidine type functionality and a carboxylic moiety.122
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Figure 3. Structurally diverse RGD peptides characterized in this study, including
lactam-cyclized, disulfide-cyclized, and linear RGD derivatives and a lactam-cyclized
control peptide.
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Here, we investigate structurally diverse bifunctional RGD peptides for αvβ3
integrin affinity in vitro and in vivo. Lactam-cyclized, disulfide-cyclized, and linear
RGD derivatives and a lactam-cyclized control peptide were synthesized or
purchased with and without the macrocyclic chelator DOTA for radiolabeling with
64

Cu (Figure 3). The in vitro binding affinity of the four RGD peptides towards integrin

αvβ3 was studied in a plate-based competitive binding assay as well as specificity
against αvβ5 and αIIbβ3 using the same assay. Cellular uptake studies in an αvβ3positive cell line (U87MG human glioblastoma cells) were performed using the four
different
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Cu-DOTA-labeled peptides. In vivo properties were studied via

biodistribution studies and small-animal PET imaging in U87MG tumor-bearing nu/nu
mice.

Experimental Procedures
General materials and instrumentation. All solvents and chemicals were
reagent grade and used without further purification unless otherwise noted. Nhydroxybenzotriazole (HOBt) and the Fmoc-protected amino acids were purchased
from

AnaSpec

(San

Jose,

CA).

Trifluoroacetic

acid

(TFA)

and

N,N-

diisopropylethylamine (DIEA) were purchased from Advanced ChemTech (Louisville,
KY). Dichloromethane (DCM), N, N-dimethyformamide (DMF), methanol, and
acetonitrile were from purchased from Fisher Scientific (Pittsburgh, PA). 1,4,7,10Tetraazacyclododecane-1,4,7-tris(t-butyl acetate)-10-aceitc acid

(DOTA-(3OBut)-

COOH) was purchased from Macrocyclics (Dallas, TX). Diisopropylcarbodiimide
(DIC) and other commercial chemicals were purchased from Sigma-Aldrich (St.
Louis, MO). The peptides and derivatives were obtained from a variety of sources:
KCRGDC and GRGDS were custom synthesized by Tianma Pharma Co. (Suzhou,
China); DOTA-GGRGDS was custom synthesized by C.S Bio Company, Inc. (Menlo
Park, CA); and c(RGDyK) was purchased from Peptides International, Inc.
(Louisville, KY). Yunpeng Ye synthesized DOTA-c(RGDyK) and DOTA-KCRGDC.
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Vitronectin, fibronectin, αvβ3 and αvβ5 were purchased from Chemicon (a division of
Millipore; Bellerica, MA). Integrin αIIbβ3 was purchased from EMD Chemicals, Inc.
(Gibbstown, NJ). All solutions were prepared using water which had been distilled
and then deionized (18 MΩ/cm2) by passing through a Milli-Q water filtration system
(Millipore Corp.; Bedford, MA). Trace metals were removed from all buffers used for
radiolabeling by Chelex 100 resin (BioRad Laboratories; Hercules, CA). Whatman
C18 silica gel TLC plates (KC18F, 60 Å, 200 µm) were purchased from Fisher
Scientific (Pittsburgh, PA). Copper-64 was prepared on a biomedical cyclotron at
Washington University Medical School by the
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Ni(p,n)64Cu nuclear reaction at high

specific activity as previously described.103 Female nu/nu mice were purchased from
Charles River Laboratories (Boston, MA). ES-MS was accomplished using a Waters
Micromass ZQ (Millford, MA). Radio-TLC was accomplished using a Bioscan 200
imaging scanner (Bioscan, Inc., Washington, DC). Analytical reversed-phase HPLC
was performed on a Waters 600E (Milford, MA) chromatography system with a
Waters 991 photodiode array detector and an Ortec Model 661 radioactivity detector
(EG&G Instruments, Oak Ridge, TN). Radioactive samples were counted with a
Beckman 8000 automated well-type gamma counter (Beckman Instruments, Inc.;
Fullerton, CA) or a Wallac Wizard 1480 automatic gamma counter (Perkin Elmer;
Gaithersburg, MD).
HPLC purification and analysis for peptide synthesis. HPLC analysis was
performed with a Vydac C-18 column (250 × 4.6 mm) at a flow rate of 1.0 mL/min.
Semi-preparative HPLC was performed with a Vydac C-18 column (25 × 2.2 cm) at
9.5 mL/min. HPLC eluents consist of water containing 0.05% TFA (solvent A) and
acetonitrile containing 0.05% TFA (solvent B). The elution profile was monitored by
UV absorbance at 254 nm and 214 nm.
Solid phase peptide synthesis of H-DTyr(But)-Lys(Dde)-Arg(Pbf)-AlaAsp(OBut)-OH. The protected peptide sequence was assembled manually from HAsp(But) 2-chlorotrityl resin (0.81 g, 0.64 mmol/g) using the conventional Fmoc
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chemistry in a glass reaction vessel fitted with a sintered glass frit. The coupling
reactions were carried out by adding a pre-activated solution of N-α-Fmoc-protected
amino acid (1.2 mmol), HOBT (1.2 mmol), HBTU (1.2 mmol), and DIEA (2.4 mmol) in
anhydrous DMF (3 mL/g resin) into the resin and swirling for 2 h. The progress of the
coupling was monitored by Kaiser test. The Fmoc protecting groups were removed
with a solution of 20% piperidine in DMF (10 min, 2x). The resin was washed with
methanol (1 min, 2x), followed by DMF (1 min, 6x). The penta-peptide, H-DTyr(But)Lys(Dde)-Arg(Pbf)-Ala-Asp(OBut)-OH, was cleaved by swirling the resin in
trifluoroacetic acid/dichloromethane (1:99 v:v) for 5 min. The filtrate was added to a
solution of pyridine/methanol (5 mL/10 mL). The resin was washed with methanol
(2x) and dichloromethane (2x). The cleavage procedure described above was
repeated five more times and the combined filtrate was concentrated, washed with
water, and dried to give the title compound (480 mg, 94% yield).
Cyclo[DTyr(But)-Lys-Arg(Pbf)-Ala-Asp(OBut)]. The peptide obtained above
was added dropwise into a solution of PyBOP (520 mg, 1 mmol), HOBT(135 mg, 1
mmol), and DIEA (260 mg, 2 mmol) in DMF/DCM (1000 mL, 10:90 v:v). The mixture
was stirred overnight, concentrated, and washed with water, 5% aqueous potassium,
and water. The solid was dissolved in methanol (100 mL) containing hydrazine (1.0
mL). The mixture was stirred for 15 min, concentrated, and washed with aqueous
NaHCO3 solution (5%) and water. The title compound was further purified by flash
column chromatography on silica gel using a mixture of methanol, DCM, and DIEA
as eluent (155 mg, 35% yield).
Cyclo[DTyr-Lys(DOTA)-Arg-Ala-Asp]. A mixture of the peptide obtained
above (80.0 mg, 0.08 mmol), DOTA(3OBut) (82.0 mg, 0.24 mmol), HOBT (32.4 mg,
0.24 mmol), and DIC (100.8 mg, 0.80 mmol) in DMF (1.2 mL) was stirred for 72 h.
The mixture was filtered, concentrated, and stirred in aqueous TFA (95:5 v:v, 3 mL)
for 2 h. The resulting mixture was added to a solution of cold MBTE (10 mL). The
precipitate was collected by centrifugation and purified by HPLC (gradient from 3% to
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50% over a period of 20 min and then isocratic at 50% for 10 min). The desired
fractions were characterized by both ES-MS and HPLC, combined, and lyophilized to
afford the title compound (19 mg, ~15% yield), observed m/z for [MH]+ and [MH2]2+
in ES-MS: 1019.5 and 510.25.
Integrin binding assay. An isolated, competitive binding assay described
previously is utilized here. Briefly, vitronectin (Vn) and fibronectin (Fn) were
biotinylated with N-hydroxysuccinimide biotin (2 h at room temperature) before
dialysis into PBS, pH 7.4. The wells of a 96-well plate (Nunc Immuno Plate with
MaxiSorp) were coated with 100 µg integrin αvβ3, αvβ5, or αIIbβ3 in coating buffer (20
mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 10 µM MnCl2). The plates
were then blocked (1 h at 4 °C) with bovine serum alb umin (BSA) (3% in coating
buffer). After washing three times with binding buffer (0.1% BSA in coating buffer),
biotinylated Vn for integrins αvβ3 and αvβ5, or biotinylated Fn for integrin αIIbβ3, (final
concentration 14 nM) with and without serially diluted ligands was allowed to bind to
the integrins (3 h at 37 °C). After washing (200 µL binding buffer, 3x), bound
biotinylated ligand was detected by binding ExtrAvidin alkaline phosphatase
(1/35,000 dilution, 1 h at room temperature) and using the p-nitrophenyl phosphate
substrate solution as the chromogen. Each concentration data point was done in
triplicate, and each binding experiment was performed at least twice. Nonlinear
regression was used to fit binding curves and calculate inhibitory concentrations of
50% (IC50 value). A control assay was performed concurrently with all experiments to
ensure the accuracy of the procedure and reagents.
Radiolabeling with
radiolabeled with

64

64

Cu. Each of the DOTA-RGD-peptide constructs was

Cu in aqueous solution following the general procedures for

radiolabeling non-cross-bridged ligands that have been previously described.79 In
brief, no-carrier-added

64

CuCl2 was added to a 5 mM solution of DOTA-peptide

conjugate in 0.1 M NH4OAc, pH 8 and heated at 37 °C for 45 – 90 min. Specif ic
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activities ranging from 1 - 2.8 mCi/µg were obtained. Radiochemical purity of ≥ 95 %
was verified by radio-TLC and radio-HPLC.
Cellular internalization assay. The U87MG human gliobastoma cell line
(integrin αvβ3-positive) was obtained from American Tissue Culture Collection
(Manassas, VA) and maintained at 37 °C in a humidified environment containing 5 %
CO2 in Eagle’s Minimum Essential medium (with Earle’s BSS and 2mM L-glutamine)
(MEM) supplemented with 10% fetal bovine serum (Invitrogen Corp., Carlsbad, CA).
For cell assays, cells were grown until 65–75 % confluent before being harvested by
incubation at 37 °C for two min in trypsin/EDTA soluti on. The cell samples were
centrifuged at 110 g for 5 min. The cell pellets were rinsed with growth medium (2 x 1
mL) and resuspended in the binding medium (MEM, 1 % glutamine, 1 % BSA, 0.1
mM Mg2+, 0.1 mM Mn2+) (1×106 cells/(0.5) mL) in microfuge tubes. The

64

Cu-DOTA-

peptide solution (1 nM, ~5 µCi in 20-30 µL) was added to the cell suspension, and
the samples were incubated (37 °C, 5 % CO 2) with rotation for 15, 30, 60, 90 min.
For block experiments the samples were administered 1 µM non-radioactive peptide
solution (50 µL) 15 min prior to addition of the

64

Cu-DOTA-peptide solution. At

appropriate time points, the samples were centrifuged for 1 min at 110 g and the
radioactive medium was aspirated. Cell pellets were rinsed with ice cold binding
buffer (0.5 mL) and centrifuged for 1 min at 110 g (2x). Suspension of the cells in
acidic wash buffer (HBSS containing 20 mM NaOAc (pH 4.0)) (0.5 mL, 2x) and
incubation at 37 °C for 10 min was used to isolate the surface bound fraction. The
cells were separated from the surface bound fraction by centrifugation and collection
of the supernatant; the resulting two acid wash fractions were combined. The cellinternalized fraction was obtained by lysing the cell pellets in lysis buffer (1 mL 0.5 %
SDS in PBS). The radioactivity in each fraction was measured in a well-type gamma
counter. Total protein concentration was determined using the bicinchoninic acid
protein assay (Pierce Biotechnology, Rockford, IL). Uptake was normalized by
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expression as % activity administered per milligram of protein. Each peptide and time
point was done in triplicate.
Biodistribution studies. Animal experiments were carried out under humane
conditions and in compliance with the Guidelines for the Care and Use of Research
Animals established by Washington University’s Animal Studies Committee. Female
athymic nude mice (nu/nu) (6 wk old) were given subcutaneous injections at the
nape of the neck with 5 x 106 U87MG glioblastoma cells suspended in a minimal
volume of PBS. After 3.5 weeks the tumor-bearing mice were subject to
biodistribution and small-animal PET imaging studies.
Tissue distribution studies were performed after intravenous injection of the
radiolabeled compound via the tail vein (20-30 mCi in 100-150 µL). A blocking
experiment was also performed by coinjecting radiotracer with a saturating dose of
cold peptide (18 mg/kg mouse body weight). Tissue biodistribution data were
obtained at 1, 4, and 24 h post injection (PI) and 1 h block (n = 5 per time point).
Animals were sacrificed at the appropriate time points, organs of interest, including
tumor, were removed and weighed, and the radioactivity was measured in a gamma
counter along with dose standards. The raw counts were decay corrected to a
standard time, and the counts were normalized as the percent total inject dose per
gram of tissue (%ID/g) and percent injected dose per organ (%ID/organ). Mice were
allowed food and water ad libitum.
microPET imaging. Whole-body small animal PET imaging was performed
on a microPET Focus 120 or 220 small-animal PET scanner (CTI-Concord
Microsystems LLC, Knoxville, TN). Mice anesthetized with 1-2 % isoflurane were
imaged for 10 min at 1, 4 and 24 h after tail vein injection of the 64Cu-DOTA-peptide.
Co-registration of the small-animal PET images was achieved in combination with a
microCAT-II small-animal CT camera (CTI-Imtek Inc., Knoxville, TN) which provides
high-resolution CT anatomic images. Co-registration of microPET and microCAT
images was accomplished through a landmark registration technique with image
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display software (Amira, TGS Inc.) using fiducial markers directly attached to the
animal bed. Maximum a posteriori (MAP) reconstruction was used for the PET
component of the co-registered images. Regions of interest (ROI) were drawn
manually based on co-registered small-animal CT images, and ROI activity on the
corresponding small-animal PET images was measured using Amira 4.0 software
(Visage Imaging Inc., San Diego, CA). These values were converted to standard
uptake values (SUVs) using equation 1.

SUV =

tissue concentration (µCi/g)
injected dose (µCi) / body weight (g)

(Eq. 1)

After imaging, the mice were sacrificed for post-PET biodistribution, as described
above.
Statistical methods. All data are presented as the mean ± standard
deviation. Group comparisons were made using standard ANOVA methods. Post-hoc
testing of individual group differences was accomplished with the Bonferroni test.
Groups with p < 0.05 were considered significantly different. GraphPad Prism
software (version 5.02; San Diego, CA) was used for all statistical analyses.
Collaborators. Synthesis of the peptides described in the experimental
section was carried out in the laboratory of Dr. Sam Achilefu by ALF. Details for the
synthesis of DOTA-c(RGDyK) and DOTA-KCRGDC by Yunpeng Ye can be found in
Appendix II.

Results
Solid phase peptide synthesis. As shown in Scheme 1, the cyclic protected
RGD peptide i.e. cyclo[R(Pbf)GD(OBut)y(But)K] was similarly prepared as reported
previously. The linear protecting peptide H-D(OBut)y(But)K(Dde)R(Pbf)G-OH was
assembled from H-Gly-2-chlorotrityl resin using conventional Fmoc chemistry and
then cleaved with 1% TFA in DCM. The crude product was cyclized in the presence
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of PyBOP/HOBT/DIEA in a diluted solution in DCM/DMF (90:10). The resulting cyclic
protected peptide i.e. cyclo[R(Pbf)GD(OBut)y(But)K(Dde)] was further de-protected
with 2% hydrazine in methanol to afford the desired amino-containing analog i.e.
cyclo[R(Pbf)GD(OBut)y(But)K], which was confirmed by ES-MS. This peptide was
conjugated with DOTA(3OBut)-COOH in the presence of HOBT and DIC to give
cyclo[R(Pbf)GD(OBut)y(But)K(DOTA(3OBut)] which was de-protected with TFA. The
crude product was purified by semi-preparative HPLC to get the desired product, i.e.
cyclo[RGDyK(DOTA)].

H-Gly-O
2

1

H-Asp(OBut)-DTyr(But)-Lys(Dde)-Arg(Pbf)-Gly-O

H-Asp(OBut)-DTyr(But)-Lys(Dde)-Arg(Pbf)-Gly-OH

3
Cyclo[DTyr(But)-Lys(Dde)-Arg(Pbf)-Gly-Asp(OBut)]
4
Cyclo[DTyr(But)-Lys-Arg(Pbf)-Gly-Asp(OBut)]
5

Cyclo{DTyr(But)-Lys[DOTA(3OBut)]-Arg(Pbf)-Gly-Asp(OBut)}

6
Cyclo[DTyr-Lys(DOTA)-Arg-Gly-Asp]

Reagents and conditions:
1. Fmoc chemistry; 2. a) TFA/DCM(1:99); b) Pyridine/DCM/Methanol;
3. PyBOP/HOBT/DIEA/DMF/DCM; 4. Hydrazine/methanol(1:100);
5.DOTA(3OBut)-COOH/HOBT/DIC/DMF; 6. TFA/water(95:5).

Scheme 1. Synthesis of cyclo[RGDyK(DOTA)]

As summarized in Scheme 2, the resin-bound linear protected peptide i.e.
Fmoc-Lys(Boc)-Cys(Acm)-Arg(Pbf)-Gly-Asp(OBut)-Cys(Acm)-Rink amide resin was
assembled from Fmoc-Rink amide resin using Fmoc chemistry. The disulfide bond
was formed with thallium trifluoroacetate in DMF on solid support. After the Fmoc at
the N-terminus was deblocked with 20% piperidine in DMF, the DOTA(3OBut)-COOH
was attached in the presence of HOBT and DIC. Finally, the desired product, i.e.
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DOTA-K-cyclo(CRGDC)-NH2, was obtained by cleavage with TFA/water (95:5) was
purified by HPLC. The two desired products were identified by both ES-MS and
analytical HPLC.

1

Fmoc-NH

Fmoc-Lys(Boc)-Cys(Acm)-Arg(Pbf)-Gly-Asp(OBut)-Cys(Acm)

S
S
t
Fmoc-Lys(Boc)-Cys-Arg(Pbf)-Gly-Asp(OBu )-Cys-NH

2

3

4

S
S
DOTA(3OBut)-Lys(Boc)-Cys-Arg(Pbf)-Gly-Asp(OBut)-Cys-NH
S
S
DOTA-Lys-Cys-Arg-Gly-Asp-Cys-NH2

Reagents and condition: 1. Peptide assembly using Fmoc chemistry; 2. Tl(CF3COO)3/DMF;
3. (a) piperidine/DMF(20%); (b) DOTA(3OBut)/HOBT/DIC/DMF; 4. TFA/water(95:5).

Scheme 2. Synthesis of DOTA-K-cyclo(CRGDC)-NH2.

The cyclic control peptide was prepared in three steps consisting of solid
phase peptide synthesis, intramolecular cyclization in solution, and conjugation of
peptide with DOTA, as shown in Scheme 3. Briefly, the orthogonally protected linear
peptide [DTyr(But)-Lys(Dde)-Arg(Pbf)-Ala-Asp(OBut)-O-Resin] was prepared on a 2chlorotrityl resin and cleaved with 1% TFA in dichloromethane (DCM). After cyclizing
the protected peptide in a solution of PyBOP (2.5 equiv), HOBT (2.5 equiv), and
DIEA (5 equiv) in DMF/DCM (1:10 v:v), the Dde group was selectively removed with
1% hydrazine in methanol. DOTA(3OBut) (3 equiv) was conjugated to the free εamino lysine group of the peptide (1 equiv) in the presence of DIC (10 equiv), and
HOBT (3 equiv) in anhydrous DMF. All side-chain protecting groups were removed
with 95% aqueous TFA solution and the crude product was purified by HPLC and
identified by ES-MS.
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H-Asp(OBut)-O
2

3

1

H-DTyr(But)-Lys(Dde)-Arg(Pbf)-Ala-Asp(OBut)-O

H-DTyr(But)-Lys(Dde)-Arg(Pbf)-Ala-Asp(OBut)-OH

Cyclo[DTyr(But)-Lys(Dde)-Arg(Pbf)-Ala-Asp(OBut)]

4
Cyclo[DTyr(But)-Lys-Arg(Pbf)-Ala-Asp(OBut)]
5
Cyclo[DTyr(But)-Lys(DOTA(3OBut))-Arg(Pbf)-Ala-Asp(OBut)]
6
Cyclo[DTyr-Lys(DOTA)-Arg-Ala-Asp]
Reagents and conditions: 1. Fmoc chemistry; 2. a) TFA/DCM(1:99); b) Pyridine/DCM/Methanol;
3. PyBOP/HOBT/DIEA/DMF/DCM; 4. Hydrazine/methanol(1:100);
5. DOTA(3OBut)/HOBT/DIC/DMF; 6. TFA/water(95:5).

Scheme 3. Synthesis of cyclo[RADyK(DOTA)]

Integrin binding assay. Inhibitory effects of structurally diverse RGD
peptides were quantified by measuring their effects on the interactions between
immobilized integrin and biotinylated soluble Iigands (Table 1). Figure 4 shows
representative IC50 binding curves of GRGDS towards integrins αvβ3, αvβ5, and αIIbβ3.
The IC50 values obtained in replicate experiments were within the same confidence
interval. The ability of the peptides to inhibit the binding of vitronectin to the isolated
immobilized αvβ3 and αvβ5 receptor was compared with the previously published
values for c(RGDyK). In some instances inhibitory peptides were able to suppress
fully the binding of ligands to the isolated receptors. All the binding kinetics followed
a classic sigmoid path and could be fit with a nonlinear regression curve. According
to the IC50 values obtained, KCRGDC has the best selectivity for integrin αvβ3 and its
binding specificity is comparable to c(RGDyK), which has the lowest IC50 value.
Whereas Haubner et al. found selectivity of all peptides to be similar, with biological
activities about 4000 times higher for the αvβ3 integrin over αIIbβ3, that trend was only
observed here for the disulfide-cyclized KCRDGDC. The lactam-cyclized peptide,
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c(RDGyK), was found to have a 30-fold better affinity for αIIbβ3 compared to αvβ3.
This was surprising but has not been further investigated. A previous study by Pfaff
et al., using a similar binding assay, reported a similar affinity of the linear peptide
GRGDS towards αvβ3 and αIIbβ3 as was observed here (30-fold increase verse 55-

% Native Ligand Bound

fold increase).
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Figure 4. IC50 binding curves for GRGDS versus vitronectin for integrins
αvβ3 and αvβ5 and versus fibronectin for αIIbβ3 (n=3).

Table 1. Inhibition of Vitronectin Binding to Immobilized αvβ3 and αvβ5 and Fibrinogen
Binding to Immobilized αIIbβ3 in a Competative Heterologous Binding Assay.
IC50
αvβ3 (nM)

αvβ5 (nM)

αIIbβ3 (nM)

c(RGDyK)

3.7a

194a

0.11

KCRGDC

10.4

921

> 5,000

GRGDS

15.9

> 5,000

873

c(RADyK)

1,400

> 5,000

a: previously published values

64

> 5,000
103

Cellular internalization assay. Cell-based assays were performed with
64

Cu-DOTA-peptides to measure the internalization efficiency of the peptides in

U87MG glioblastoma cells. Internalization of the radioactivity as well as total cell
associated activity were measured at several time-points over 90 min and
normalized to protein content (Figure 5). In order to better visualize the differences
between the compounds, internalization and total cell associated activity of all four
compounds after 60 min are presented on one graph (Figure 6). For the three

64

Cu-

DOTA-RGD compounds, total cell associated activity continues to increase for the
entire time although internalization does not. The disulfide-cyclized

64

Cu-DOTA-

KCRGDC has statistically significant higher levels of non-blocked internalization (p <
0.001) and total cell associated activity (p < 0.05) compared to the three other
compounds. The binding and internalization trends of

64

Cu-DOTA-GGRGDS and

64

Cu-DOTA-c(RGDyK) are the same with slightly less uptake observed for

64

DOTA-c(RGDyK), although not statistically significant. Binding and uptake of

64

DOTA-RGD peptides could be blocked by addition of excess cold peptide.
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CuCu-

Figure 5. Comparison of cellular internalization and cell-associated activity in
U87MG cells over time (n = 3). (A)

64

Cu-DOTA-KCRGDC, block with KCRGDC; (B)

64

Cu-DOTA-GGRGDS, block with GRGDS; (C)

64

Cu-DOTA-c(RGDyK), block with

c(RGDyK); (D) 64Cu-DOTA-c(RADyK), block with c(RGDyK). Note the different y-axis
scale used for (A) and (D).
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Specific, blockable cell surface binding is observed for 64Cu-DOTA-c(RADyK),
although only minimal internalization is observed. Total cell associated (p < 0.001)
and internalization (p < 0.05) without blocking are significantly lower for the control
compared to the RGD peptides.

Figure 6. Comparison of cellular internalization and cell-associated activity at 60 min
in U87MG cells for four 64Cu-DOTA-peptides (n = 3).

In vivo characterization. Small-animal PET and CT co-registration was
performed with two of the

64

Cu-DOTA-peptide constructs,

64

Cu-DOTA-KCRGDC and

64

Cu-DOTA-GGRGDS (n = 2 with and without block), simultaneously with

biodistribution studies. Biodistribution was also performed with

64

Cu-DOTA-

c(RGDyK). A comparison of biodistribution in selected organs is presented in Figure
7, showing rapid uptake and retention of the 64Cu-labeled peptides in tumor.
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Figure 7. Comparison of biodistribution of selected organs in U87MG tumor-bearing
nu/nu mice (n = 5). (A)

64

Cu-DOTA-KCRGDC, block with KCRGDC; (B)

GGRGDS, block with GRGDS; (C)

64

64

Cu-DOTA-

Cu-DOTA-c(RGDyK), block with c(RGDyK).

(* p < 0.05 compared to non-blocked.)
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Significantly higher levels of uptake were observed for
across all organs. As observed in the cell studies,

64

Cu-DOTA-KCRGDC

64

Cu-DOTA-GGRGDS and

64

Cu-

DOTA-c(RGDyK) have similar profiles. The disulfide-cyclized peptide was the only
compound observed to have increased tumor uptake from 4 to 24 h PI (64Cu-DOTAKCRGDC, 9.4% increase;

64

Cu-DOTA-GGRGDS, 20.4% decrease;

64

Cu-DOTA-

c(RGDyK), 22.5% decrease). This was also the only peptide to have continuous
64

blood clearance over the 24 h period (from 1 to 24 h PI:
28.4% decrease;

64

Cu-DOTA-GGRGDS, 28.2% incease;

Cu-DOTA-KCRGDC,

64

1.0% increase). The increased blood activity observed for

Cu-DOTA-c(RGDyK),

64

Cu-DOTA-GGRGDS

suggests that the compound is unstable in vivo which would contribute to its overall
poor biodistribution. All three compounds have similar rates of clearance for liver and
64

kidney (percent reduction in kidney from 1 to 24 h:
64

Cu-DOTA-GGRGDS, 30.8%;

kidney from 1 to 24 h:

Cu-DOTA-KCRGDC, 18.4%;

64

Cu-DOTA-c(RGDyK), 27.9%) (percent reduction in

64

Cu-DOTA-KCRGDC, 46.8%;

64

Cu-DOTA-c(RGDyK), 73.3%). Tumor uptake of

64

Cu-DOTA-GGRGDS, 50.4%;

64

Cu-DOTA-c(RGDyK) can be

blocked by co-administration of high doses of unlabeled peptide (1 h PI: non-block,
1.8875±0.2396; block, 0.7723±0.1458 (p < 0.05)). Blocking of
and

64

Cu-DOTA-KCRGDC

64

Cu-DOTA-GGRGDS uptake at 1 h was not attained with either co-injection or

pre-injection (15 min or 1 h) of cold peptide (pre-blocking data not shown).
Good tumor:blood and tumor:muscle ratios were observed for the three
compounds tested. At 4 h post-injection tumor:muscle ratios for all three compounds
were similar (Figure 8). The lactam-cyclized
significantly higher tumor:blood ratio (p< 0.001).
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64

Cu-DOTA-c(RGDyK) has a

Figure 8. Comparison of tumor:background tissue ratios. (*p < 0.001 compared to
64

Cu-DOTA-c(RGDyK).)

The coregistered PET/CT images shown in Figures 9 and 10 are
representative of all mice in each group (n = 2). In coronal and transaxial sections
uptake in the tumor can be visualized. As observed in the biodistribution study at 1 h,
there is no significant difference between those animals receiving a blocking dose of
peptide or not at 1, 4, or 24 h PI (SUV at 4 h PI:
64

Cu-DOTA-KCRGDC + block, 0.98±0.36;

64

64

Cu-DOTA-KCRGDC, 0.79±0.17;

Cu-DOTA-GGRGDS, 1.45±0.23;

64

Cu-

DOTA-GGRGDS + block, 1.58±0.075) (Figure 11). The best tumor visualization was
obtained at 4 h PI and is supported by the highest SUV values of the three time
points. Following the 24 h imaging timepoint, a post-PET biodistribution was
performed (Figure 12). The activity distributions are comparable to those observed in
the other biodistribution studies (Figure 7) and support the imaging observations. At
24 h there is not statistically significant difference in tracer uptake and retention
between animals receiving a dose of cold peptide block at time 0 and those which
did not.
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Figure 9. Small-animal PET/CT of

64

Cu-DOTA-KCRGDC uptake in U87MG tumor-

bearing nu/nu mice (static image obtained 4 h PI, 10 min scan). Block with KCRGDC
on left in both panels. (A) Coronal slice with tumor (T), liver (L), and fiducial (*)
indicated. (B) Transaxial slice with tumor indicated.
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Figure 10. Small-animal PET/CT of

64

Cu-DOTA-GGRGDS uptake in U87MG tumor-

bearing nu/nu mice (static image obtained 4 h PI, 10 min scan). Block with GRGDS
on right in both panels. (A) Coronal slice with tumor (T), liver (L), and fiducials (*)
indicated. (B) Transaxial slice with tumor and fiducial indicated.
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Cu-DOTA-KCRGDC
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Figure 11. Standard uptake values for 64Cu-DOTA-RGD peptides in U87MG tumor.

Figure 12. Comparison of post-PET imaging biodistribution in U87MG tumor-bearing
nu/nu mice (24 h PI) (n = 2).
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Discussion and Conclusions
The goal of this study was to systematically evaluate the affinity, receptor
specificity, cellular internalization and tumor localization properties of a series of
structurally diverse RGD peptides. A lactam-cyclized, disulfide-cyclized, and linear
peptide, as well as a lactam-cyclized control were selected for evaluation. While
none of these peptides are novel, they have not previously been rigorously studied
using the same assays to allow for direct comparison of their respective in vitro and
in vivo properties. The results are useful for the design and evaluation of future
integrin αvβ3 imaging agents.
Peptides were screened against the integrins αvβ5 and αIIbβ3, found on
macrophages and platelets respectively, to evaluate the specificity of the compounds
towards the integrin αvβ3. The cyclic lactam c(RGDyK) peptide sequence is known to
possess high affinity and selectivity for αvβ3 relative to αvβ594; however, it’s high
affinity for αIIbβ3 was surprising and could contribute to high background in imaging
studies. The more than five hundred-fold enhancement of binding of KCRGDC
towards αvβ3 compared with αIIbβ3, and hundred-fold compared to αvβ5, suggests high
selectivity. The linear peptide has similarly high selectivity, with three hundred-fold
higher affinity for αvβ5 and fifty-fold higher affinity for αIIbβ3. While αvβ3 is upregulated
in angiogenesis and other disease processes, integrins αvβ5 and αIIbβ3 are
upregulated in other disease processes and found on other non-disease cells. Highly
selective peptide results are promising for application in clinical imaging and
therapeutic settings.
The cell-based assays were performed to evaluate the internalization
efficiency of the peptides in αvβ3–positive cells. Block experiments performed with an
excess of non-radiolabeled peptide resulted in significantly lower levels of
internalization for all peptides studied and is consistent with receptor mediated
endocytosis of the radiotracer. Additionally, whole cell assays introduce factors not
present in the isolated receptor binding assays carried out with purified proteins and
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allowed for confirmation of the receptor specificity of the observed binding.
Internalization of each of the RGD peptides was observed with varying extents
64

Cu-DOTA-KCRGDC >

64

Cu-DOTA-GGRGDS ~

64

Cu-DOTA-c(RGDyK). Although

in the isolated binding assay c(RADyK) showed low affinity for αvβ3, specific,
blockable cell surface binding was observed. Therefore, this compound will not serve
as a good negative control in vivo. Investigation of another variant, c(GREyK), which
has also demonstrated low affinity towards the isolated integrins, is being studied.
The U87MG glioblastoma tumor model has been well-established to have a
high level of integrin αvβ3 expression.143 Tumor uptake and retention of
KCRGDC was five to ten times higher than either

64

Cu-DOTA-

64

Cu-DOTA-GGRGDS or

64

Cu-

DOTA-c(RGDyK). This disparity led to nearly identical tumor:background ratios for
each compound at all time points. The high tumor:blood ratio for

64

Cu-DOTA-

c(RGDyK) combined with the observed ability to block tumor uptake with coadministration of an excess of unlabeled peptide, suggests that in vivo imaging
would afford tumor visualization. Chen, et al. reported the use of

64

Cu-DOTA-

c(RGDyK) for tumor angiogenesis imaging in MDA-MB-435 tumor-bearing mice.144
They observed prolonged tumor retention and persistent uptake in the liver, with
strong contrast from the background tissue in microPET imaging.
64

Attempts to demonstrate that

Cu-DOTA-KCRGDC and

64

Cu-DOTA-

GGRGDS accumulation in the tumor was receptor specific, were not successful.
Coadministration of a competitive dose of KCRGDC or GRGDS was ineffective in
blocking in vivo tumor uptake of

64

Cu-DOTA-KCRGDC or

64

Cu-DOTA-GGRGDS,

respectively. The chosen blocking quantity, 18 mg/kg, was based on previous work
that showed it was sufficient to completely inhibit radiolabeled RGD peptide
analogues in αvβ3-positive tissue.103, 145 While we observed partial inhibition of
DOTA-c(RGDyK) accumulation, neither

64

Cu-DOTA-KCRGDC nor

64

Cu-

64

Cu-DOTA-

GGRGDS accumulation was inhibited at this dosing level, a thousand-fold excess of
the administered dose of radiolabeled peptide. While many groups have reported
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successful in vivo blocking, we are not the first to report difficulty blocking in vivo
accumulation despite the ability to efficiently block accumulation in vitro.146 The lack
of competitive inhibition may be due to differing clearance properties between the
radiolabeled

64

Cu-DOTA-peptide and the peptide, extremely rapid recycling of

integrin αvβ3 following peptide-mediated internalization, or a combination of the
two.147
Small-animal imaging of

64

Cu-DOTA-KCRGDC and

64

Cu-DOTA-GGRGDS in

a murine U87MG tumor model demonstrated tumor uptake for both compounds.
There is good correlation between the observed liver and kidney accumulation by
microPET and the tissue biodistribution measurements. The images produced with
the linear peptide,

64

Cu-DOTA-GGRGDS, have a noisy, non-uniform distribution

through the tissues with radiotracer uptake, but the tumor is discernable, aided by
coregistration with microCT. Neither specific activity nor injected dose has been
optimized to improve tumor visualization. Previously, it has been reported that the
linear peptides do not accumulate in tumor and are not clearly visualized in smallanimal imaging148 due to poor in vivo stability.110 While the tumor could be visualized
with 64Cu-DOTA-GGRGDS on a coregistered PET/CT image, the clarity of the image
is worse than that of the

64

Cu-DOTA-KCRGDC images. Cyclic peptides seem to be

more resistant to proteolysis, and their conformationally constrained state traps them
in the active conformation. Thus, cyclization improves tumor targeting efficiency.
While the disulfide-cyclized
behavior,

64

Cu-DOTA-KCRGDC exhibits the best in vitro

64

Cu-DOTA-c(RGDyK) has better in vivo properties. The benefits of the

synthetic simplicity afforded by a disulfide-cyclized peptide versus a lactam-cyclized
one must be weighed against the improved in vivo performance. Future studies with
new versions of RGD peptide amphiphiles may produce compounds in which these
properties are not in opposition.
Further in vivo investigation of the compounds reported upon here is
warranted to demonstrate targeting specificity of the peptides along with exploration
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of a different peptide as a negative control. Improved pharmacokinetics of RGDpeptide based radiopharmaceuticals would also be necessary for successful
adoption as diagnostic imaging or radiotherapeutic agents. Higher binding affinity is
being investigated through multimeric peptides and conjugation of several peptides
onto the surface of nanoparticles. High αvβ3 binding affinity and specificity along with
good

in

vivo

pharmacokinetics

would

enable

RGD-peptide

based

radiopharmaceuticals to be used for diagnostic imaging and as therapeutic agents
for cancer and other αvβ3-expressing disease states.

77

CHAPTER 4

Preparation, Purification, and In Vitro Characterization
of RGD-Functionalized Shell Crosslinked Nanoparticles
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Abstract
In this work, micelles and shell crosslinked nanoparticles (SCKs) prepared
from poly(acrylic acid)-b-polystyrene (PAA-b-PS) were labeled with the cyclic peptide
KCRGDC, as nanoscale agents for non-invasive imaging and targeted drug delivery.
This peptide contains the tripeptide arginine-glycine-aspartic acid (RGD) sequence
as the recognition motif for the αvβ 3 integrin receptor, which is highly expressed in
areas where angiogenesis occurs. Methods were developed to afford nanoparticles
labeled with covalently attached and ready-to-bind KCRGDC peptide. The binding of
these peptide-labeled nanoparticles was evaluated by measuring IC50 values to αvβ 3.
In order to specifically target the αvβ3 integrin, selectivity against another integrin,
αvβ 5, was also demonstrated. The best affinity to αvβ3 was achieved by attaching the
KCRGDC

peptide

to

the

micelle

assembled

from

HOOC-PEG30004.0-g-

DOTAlysine3.2-g-PAA58.2-b-PS71, with IC50 value being 0.49 nM, a significant
enhancement from that of the KCRGDC, whose IC50 value to αvβ 3 is 10.5 nM. These
materials are of interest for cancer imaging and therapeutic delivery and in vitro cell
assay experiments should be performed to determine cellular binding and
internalization.
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Introduction
Angiogenesis is a physiological process involving the growth of new blood
vessels from existing vasculature.149

It is a normal process involved in many

biological processes, e.g. embryogenesis, wound healing, and tissue remodeling;
however, it is also a fundamental step in the transition of tumors from a dormant
state to a malignant one. Several disorders are characterized by either an excess or
insufficient number of blood vessels, e.g. rheumatoid arthritis38, psoriasis150,
restenosis151, and diabetic retinopathy152.
Angiogenesis is a multi-step, invasive process, characterized by endothelial
cell

proliferation,

modulation

of

the extracellular

matrix

(ECM),

and

cell

adhesion/migration. Among the many angiogenic factors, integrin αvβ3 has been
found to be necessary for the formation, survival, and maturation of new blood
vessels.153

In human melanoma cells, the expression of αvβ3 is correlated with

malignancy grade, collagenase production, and cell growth.154,

155

Due to integrin

αvβ3’s key role in many physiological processes, it has been evaluated extensively as
a drug target.

The tripeptide sequence arginine-glycine-aspartic acid (RGD) is

common to various ECM proteins, e.g. vitronectin, fibronectin, fibrinogen,
thrombospondin, and von Willebrand factor, involved in cell-matrix adhesion.31,

156

High-affinity αvβ3 selective ligands containing RGD have been identified by phage
display.157 Targeted chemotherapy has been investigated using RGD peptides to
deliver doxorubicin158 and proapoptotic peptides159 to tumor vasculature.

In vivo

imaging of sites of angiogenesis has been demonstrated using RGD-containing
peptides.160, 161
Since the RGD-sequence is conserved in all native ligands, differences in
binding affinities and specificity can be obtained from slight modifications.

The

flanking amino acid residues, especially the two positions following the aspartic acid,
are known to affect binding affinity both by direct interaction of the residues with the
integrin as well as influencing peptide folding.156 Cyclization is a common technique
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to improve binding properties because it confers rigidity on the structure.162
selective RGD peptides have at least one ring structure.

All

It has been recently

reported that multimeric RGD peptides can enhance the affinity of the receptor-ligand
interaction through either multivalent binding or statistical rebinding. Polyvalency
affords better targeting capability and higher cellular internalization because of
increased apparent ligand concentration.163

The unique structural properties of

nanoscale materials provide the ability for them to carry therapeutic agents and to
present numerous targeting moieties as well. Furthermore, multivalency has been
shown to facilitate internalization.47 Carrier systems like liposomes,164 polymers,165167

nanoparticles,168 and proteins169 bearing multiple RGD peptides are therefore

more likely to be internalized via receptor-mediated endocytosis than single peptide
constructs.
In this work, the disulfide-cyclized KCRGDC peptide was selected as the
antagonist to αvβ3, while shell crosslinked nanoparticles (SCKs) were used as the
carrier system. SCKs are self-assembled core-shell nanomaterials, originating from
crosslinking the shell domain of micelles assembled from amphiphilic block
copolymers, poly(acrylic acid)-b-polystyrene (PAA-b-PS) in this work.

The SCKs

produced have a robust structure due to the covalent crosslinking reaction, and have
controllable sizes ranging from 10 to 200 nm.170, 171 SCKs conjugated with KCRGDC
peptide were synthesized via various methods and were tested for binding affinities
to αvβ3 via in vitro plate-based assays. Improved binding affinities were achieved,
compared to the KCRGDC peptide as a small molecule that is capable only of
monovalent binding. With the enhanced blood circulation times that can be achieved
by grafting poly(ethylene glycol) from the nanoparticles,172 these multi-functional
materials could be good candidates as carrier systems for imaging and therapeutic
agents, selectively to injured or diseased tissues that overexpress αvβ3.
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Experimental Procedures
General Materials and Methods. All chemicals were purchased from SigmaAldrich and used without further purification unless otherwise noted. Nanopure water
(18 MΩ⋅cm) was acquired by means of a Milli-Q water filtration system (Millipore
Corp.; Bedford, MA). KCRGDC was custom synthesized by Tianma Pharma Co.,
Suzhou, China, and used as received.
Integrin binding assay. An isolated, competitive binding assay described
previously83,

173

is utilized here.

Briefly, vitronectin (Chemicon CC080) was

biotinylated with N-hydroxysuccinimide biotin (2 h at room temperature) before
dialysis into PBS, pH 7.4. The wells of a 96-well plate (Nunc Immuno Plate with
MaxiSorp) were coated with 100 µg integrin αvβ3 or αvβ5 (Chemicon CC1019 and
CC1025, respectively) in coating buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM
CaCl2, 1 mM MgCl2, 10 µM MnCl2). The plates were then blocked (1 h at 4 °C) with
bovine serum albumin (BSA) (3% in coating buffer). After washing three times with
binding buffer (0.1% BSA in coating buffer), biotinylated vitronectin (final
concentration 14 nM) with and without serially diluted ligands was allowed to bind to
the integrins (3 h at 37 °C). After washing (3 times i n binding buffer), bound
biotinylated vitronectin was detected by binding ExtrAvidin alkaline phosphatase
(1/35,000 dilution, 1 h at room temperature) using the p-nitrophenyl phosphate liquid
substrate system as the chromogen. Each concentration data point was done in
triplicate, and each binding experiment was performed at least twice.

Nonlinear

regression was used to fit binding curves and calculate inhibitory concentrations of
50% (IC50 value) (Prism, version 5.02; GraphPad).

Results and Discussion
To create a functional nanomaterial that is capable of carrying imaging and/or
therapeutic agents to a selective tissue site, it is imperative that the targeting ligand
be accessible for binding with the receptor target. Two general approaches, the
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post-conjugation method and the pre-conjugation method, were, therefore, applied to
afford micelle/SCK nanoparticles functionalized with a disulfide-cyclized RGD
peptide, KCRGDC. For the post-conjugation method, SCK nanoparticles were first
prepared from the amphiphilic diblock copolymer precursors (PAA-b-PS), according
to our established protocol, the cyclic KCRGDC peptide or the amine-terminated
PEO113-5-FAM-KCRGDC were then conjugated onto the nanoparticle shell domain
through carbodiimide-mediated aqueous amidation (see Experimental Section for
details).

For the pre-conjugation method, the PAA-b-PS block copolymers were

modified with the KCRGDC peptides via amidation chemistry in organic solvent,
followed by aqueous assembly into nanostructures and crosslinking across the shell
domain of nanoparticles.172, 174 Coincident with these synthetic efforts were rigorous
physicochemical studies to determine the composition and structure of the resulting
materials, and biological evaluations to determine the binding affinities between the
ligand bound to the nanostructure and receptors either coated on a plate or
presented on cells. The synthetic work and physicochemical studies were performed
by collaborators and details can be found in Appendix III, whereas the biological
studies were the focus of my studies.
Integrin Binding Assay. This assay tests the heterologous competitive
binding to the integrin between biotinylated vitronectin and an RGD peptide or RGDSCK construct and allows for calculation of the IC50 value. While the integrin binding
assay protocol was developed for small molecules and peptides,83 this work
demonstrates the applicability of this isolated integrin binding assay for nanoparticles
as well. The specificity of the ligand for αvβ3 is determined by measuring the affinity
for the integrin αvβ5, which is expressed on macrophages. A peptide of known
binding affinity, usually KCRGDC, was included as an external reference in each
assay.
Post-conjugation of KCRGDC peptide onto micelles and SCKs. The work
started with post attachment of the KCRGDC peptide onto micelles and SCKs
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prepared from PAA61-b-PS34 (Scheme 1 and Table 1). Nanoparticles with varied
numbers of KCRGDC were prepared by controlling the coupling stoichiometry.
Determination of the IC50 values for these samples showed that the micelle/SCKs
with no KCRGDC peptide attached showed no binding to either αvβ3 or αvβ5, at
concentrations up to 10,000 nM. For KCRGDC-labeled nanoparticles, poor binding
affinity to αvβ3 was observed for micelles and 20% crosslinked SCKs. An interesting
phenomenon is that the KCRGDC-micelle samples showed very good binding to αvβ5
instead to αvβ3, although KCRGDC has poor binding to αvβ5 as a small molecule. The
reason behind this phenomenon has not been investigated. Compared to micelles
and 20% crosslinked SCKs, enhanced and also selective binding to αvβ3 was
achieved with 50% crosslinked SCKs. Also, as the number of peptides per SCK
increased from less than 1 to c.a. 52, the IC50 value towards αvβ3 improved,
decreasing from 380 nM to 37.8 nM.

It is hypothesized that as the extent of

crosslinking increases, more of the peptides attached to the nanoparticle will be
located on the outer surface of the nanoparticles to be accessible for integrin binding,
thus improving the nanoparticles’ binding affinities as well.
peptides also leads to better binding.
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Increased loading of
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Scheme 1. Illustration of post-labeling KCRGDC peptide to micelle/SCK.

Table 1. IC50 values of KCRGDC-micelle/SCKs prepared by post-labeling method.
Samples

Naggr.

Peptide
per NPa

Peptide
per NPb

IC50 (nM)d

αvβ 3
αvβ 5
KCRGDC
10.5
921
Micelle
125
0
0
> 10,000
> 10,000
20% Crosslinked SCK 125
0
0
> 10,000
> 10,000
50% Crosslinked SCK 125
0
0
> 10,000
> 10,000
c
> 10,000
1.5
125
4
n.d.
KCRGDC-Micelle
125
40
n.d.
> 1,000
0.3
125
400
n.d.
1,080
26.1
> 5,000
> 10,000
125
4
n.d.
KCRGDC-SCKs
125
40
<1
> 1,000
> 10,000
20% Crosslinked
125
400
58
> 1,000
> 5,000
125
4
n.d.
> 1,000
> 10,000
KCRGDC-SCKs
125
40
<1
380
> 5,000
50% Crosslinked
125
400
42
37.4
> 10,000
a
nominal numbers of peptide per nanoparticle (NP) from stoichiometry; b numbers
of peptide per nanoparticle measured from Ellman’s assay; c not determined; d IC50
values for micelle/SCKs were measured to be the concentrations of the
nanoparticles in units of nM.

Post-conjugation of NH2-PEG5000-5-FAM-KCRGDC onto PEGylated SCKs
prepared

from

mPEG20005.5-g-DOTA-lysine2.5-g-PAA52-b-PS60.

Relative

to

KCRGDC, the binding affinity for KCRGDC-labeled nanoparticles to αvβ3 still needed
to be improved. Facile ways to achieve this would be to increase the peptide density
on nanoparticles or to add a spacer between KCRGDC and nanoparticles to make
the peptide more accessible for binding.

Meanwhile, besides good binding,

nanoparticles with good biodistribution are also desired. A well known method to
achieve improved biodistribution is the introduction of poly(ethylene glycol) (PEG),
grafted on the surface of particles.172,

175

To achieve this end, 20% and 50%

crosslinked SCKs prepared from mPEG20005.5-g-DOTA-lysine2.5-g-PAA52-b-PS60
which were reported to have good blood retention times were selected. The DOTAlysine here acts as a chelator for radiometal incorporation for PET imaging. A
PEGylated KCRGDC peptide, NH2-PEG5000-5-FAM-KCRGDC, was prepared. The
PEG5000 linker was used to allow the attached peptide to be more accessible for
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integrin binding, and the fluorophore, 5-FAM, was incorporated for improved
quantification of the peptide by UV-vis, thereby eliminating the need to perform the
Ellman’s assay. Scheme 2 illustrates the coupling reaction and Table 2 shows the
characterization and binding affinities of samples prepared by this method.
The coupling efficiency was found to be extremely low (0.6% and 0.4% for 20%
and 50% crosslinked PEGylated SCKs, respectively). The layer of poly(ethylene
glycol) that surrounded the SCKs can cause the low coupling efficiencies by
hindering access of the PEGylated 5-FAM-KCRGDC to the carboxyl groups in the
shell of the nanoparticles.

Compared to KCRGDC, both 5-FAM-KCRGDC and

PEG5000-5-FAM-KCRGDC showed slightly decreased binding affinities to αvβ3. Due
to the low peptide coupling, no appreciable binding to αvβ3 was observed for the two
PEGylated SCKs labeled with PEG5000-5-FAM-KCRGDC.

Table 2. IC50 values of PEGylated SCKs, post-conjugated with NH2-PEG5000-5FAM-KCRGDC.
Samples

Naggr.

Peptide
per NPa

Peptide
per NPb

IC50 (nM)c
αvβ 3
αvβ 5
23.0
> 1,000
21.3
> 1,000

5-FAM-KCRGDC
PEG5000-5-FAM-KCRGDC
20% Crosslinked PEG-5200
1000
6.3
> 1,000
> 10,000
FAM-KCRGDC-SCK
50% Crosslinked PEG-5200
1000
4.2
> 5,000
> 10,000
FAM-KCRGDC-SCK
a
targeted number of peptide per nanoparticle based on stoichiometry; b number of
peptides per nanoparticle as determined by UV-vis (ε(5-FAM-KCRGDC)492nm =
63,000 M-1cm-1); c IC50 values for micelle/SCKs were measured to be the
concentrations of the nanoparticles in units of nM.
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DOTA
PEG
KCRGDC
peptide
Scheme 2. Illustration of post-conjugation of NH2-PEO113-5-FAM-KCRGDC onto SCKs prepared from
mPEG20005.5-g-DOTA-lysine2.5-g-PAA58-b-PS54.

Pre-labeling

of

NH2-PEG5000-5-FAM-KCRGDC

onto

mPEG20005-g-

DOTA-lysine-g-PAA-b-PS, followed by micelle assembly and crosslinking into
SCKs. Due to the low peptide coupling efficiencies, NH2-PEG5000-5-FAM-KCRGDC
was pre-labeled onto mPEG20005-g-DOTA-lysine-g-PAA-b-PS block copolymers, in
DMF, to achieve better coupling through amidation chemistry facilitated by EDCI and
HOBt (Scheme 3). PAA-b-PS block copolymers with composition similar to PAA60-bPS60 were used. TEM images showed that these PEGylated micelle/SCKs were
spherical nanoparticles with narrow size distributions (Figure 1).

Detailed

characterization data and IC50 values are provided in Table 3. Compared to the postlabeling method, increased amounts of peptide were able to be incorporated onto the
nanoparticles prepared through the pre-labeling method as a result from the
increased coupling efficiency for amidation reactions carried out in DMF rather than
water.

A
B
C
D
Figure 1. Transmission electron microscopy (TEM) images of PEGylated

micelle/SCK nanoparticles, prepared from pre-labeling the NH2-PEG5000-5-FAMKCRGDC onto the amphiphilic PAA-b-PS block copolymers.

A, micelle from

mPEG20002.4-g-DOTA-lysine2.0-g-PEG5000-5-FAM-KCRGDC0.6-g-PAA59-b-PS54; B,
50% crosslinked SCK from mPEG20002.4-g-DOTAlysine2.0-g-PEG5000-5-FAMKCRGDC0.6-g-PAA59-b-PS54; C, micelle from DOTAlysine2.5-g-PEG5000-5-FAMKCRGDC0.5-g-PAA65-b-PS70; D, 50% crosslinked SCK from DOTA-lysine2.5-gPEG5000-5-FAM-KCRGDC0.5-g-PAA65-b-PS70. Scale bar 100 nm.
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Scheme 3. Graphic representation of the synthesis PEGylated SCKs labeled with KCRGDC peptide by pre-labeling
NH2-PEO113-5-FAM-KCRGDC onto the SCK precursor, mPEG2000-g-DOTAlysine-g-PAA-b-PS.

Initially, nanoparticle samples were purified by dialysis in MWCO 100 kDa
dialysis tubings to remove non-covalently bound NH2-PEG5000-5-FAM-KCRGDC
(samples 2-4 in Table 3). The IC50 values of these nanoparticles towards αvβ3 were
dramatically improved compared to samples prepared by the post-labeling method.
Unfortunately, fast protein liquid chromatography (FPLC) analysis of these
nanoparticles clearly showed that a considerable amount of non-covalently attached
NH2-PEG5000-5-FAM-KCRGDC was present. Since the shell of the nanoparticles is
composed of poly(acrylic acid) as well as mPEG2000, which can result in strong van
der Waals interactions such as hydrogen bonding between the free NH2-PEG5000-5FAM-KCRGDC and the shell/surface domain area, it made the complete removal of
the NH2-PEG5000-5-FAM-KCRGDC by dialysis difficult.
Centricon tubes (MWCO 10000 Da) were used to remove the free peptide,
making use of the shear force centifugation provides, but free peptide was still
present. These samples were also dialyzed in high salt buffer (samples 6-8), with
the expectation that high salt concentration decreases the interactions between the
peptide and the nanoparticles. After 30 d dialysis, although no free peptide was
observed by FPLC, the binding affinities of these nanoparticles also decreased. It’s
possible that the peptide might have been degraded, causing a loss of activity,
during the long dialysis.
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Table 3. Characterization data and IC50 values of micelle/SCK nanoparticles labeled with RGD peptide prepared by pre-labeling the NH2PEG5000-5-FAM-KCRGDC onto the amphiphilic PAA-b-PS block copolymers.
Polymer Precursor
y
z
m

DTEM
nm

Naggr.

entry

Samples

1

PEG5000-5-FAM-KCRGDC

2

PEG5000-5-FAM-KCRGDC-NP (micelle)

2.4

2.0

0.6

64

54

14 ± 2

240

3

PEG-5-FAM-KCRGDC-SCK-NP (50%
Crosslinked SCK)

2.4

2.0

0.6

64

54

14 ± 2

240

4

PEG5000-5-FAM-KCRGDC-NP (micelle)

0

2.5

0.5

68

70

19 ± 2

364

5

PEG-5-FAM-KCRGDC-SCK-NP (50%
Crosslinked SCK)

0

2.5

0.3

68

70

19 ± 2

364

6

PEG5000-5-FAM-KCRGDC-NP (micelle)

2.4

2.0

0.6

64

54

12 ± 2

140

x

n
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7

PEG-5-FAM-KCRGDC-SCK-NP (20%
Crosslinked SCK)

2.4

2.0

0.6

64

54

12 ± 2

140

8

PEG-5-FAM-KCRGDC-SCK-NP (50%
Crosslinked SCK)

2.4

2.0

0.6

64

54

12 ± 2

140

9

PEG5000-5-FAM-KCRGDC-NP (micelle)

5.5

2.0

1.6

64

54

12 ± 2

100

10

PEG-5-FAM-KCRGDC-SCK-NP (50%
Crosslinked SCK)

5.5

2.0

1.6

64

54

12 ± 2

100

11

PEG5000-5-FAM-KCRGDC-NP (micelle)

0

0

0.9

66

71

12 ± 2

118

12

PEG-5-FAM-KCRGDC-SCK-NP (50%
Crosslinked SCK)

0

0

0.9

66

71

12 ± 2

118

Purification method

Dialysis in MWCO 100 kDa
tubing in 5 mM PBS, pH 7.4, for
4d
Dialysis in MWCO 100 kDa
tubing in 5 mM PBS, pH 7.4, for
4d

Dialysis in MWCO 100 kDa
tubing in 150 mM PBS, pH 7.6,
for 30 d

Sephadex ® G75 (superfine)
SEC column

Sephadex ® G75 (superfine)
SEC column

a

IC50 values for micelle/SCKs were measured to be the concentrations of the nanoparticles in units of nM.

b

Limited sample size and concentration enabled a relatively low IC50 valueminimum value for these samples.

Peptide
per NP2

IC50 (nM)a
αvβ 3
αvβ 5
21.3

> 1,000

140

11.7

> 5,000

143

29.9

> 5,000

192

65.7

> 5,000

118

71.8

> 5,000

80

> 1,000

>1,000

79

388

>1,000

76

> 1,000

>1,000

158

>170b

n.d

160

>141b

n.d

104

>148b

n.d

101

>130b

n.d

D

A

C
B

not binding to αvβ3 up to 100 nM
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retention time /min

retention volume /mL

Figure 2. Fast protein liquid chromatography (FPLC) traces of A: control sample of RGD-NP prepared from Preconjugation method and purified by dialysis in 5 mM PBS (pH ~ 7.4) for 4 d; B: NH2-PEO113-5-FAM-KCRGDC; C:
control sample of RGD-NP prepared from Pre-conjugation method and purified by dialysis in 150 mM PBS (pH ~ 7.4)
for 30 d; D: sample 2 in Table 3.
.

These materials were then purified by SEC columns packed from Sephadex

®

G75 resin (bead size 20-50 µm, fractionation range 1000-50000 Da (Dextrans)).
Complete removal of the free peptide was confirmed by FPLC (Figure 2). Despite
the fact that pure samples without free peptides were obtained, the binding affinities
for αvβ3 remain worse than that of the PEGylated RGD peptide. This indicates that
the majority of the peptides attached to the nanoparticles might be located
underneath the surface and not available for binding to integrin receptors.
Post-labeling of KCRGDC to micelles functionalized with –NH-PEG-COOH
chains, targeting attachment of most of the peptides to the end of the PEG
chains to achieve better accessibility of the peptides for integrin binding. A
new method was then developed to afford nanoparticles with KCRGDC attached to
the outer surface (Scheme 4). In this method, NH2-PEG3000-COOH was attached
onto the amphiphilic block copolymer first.

The product polymer was then

assembled into micelles, with some of the PEG-COOH chains expected to spread
out on the surface of micelles. The peptide, 5-FAM-KCRGDC was then conjugated
to the micelles by methods described above. Crosslinking the shell domain with 2,2’(ethylenedioxy)bis(ethylamine) afforded the SCKs.

One micelle and one 50%

crosslinked SCK were prepared by this method. IC50 values to αvβ3 were measured,
as shown in Table 4. Compared to 5-FAM-KCRGDC, whose IC50 for αvβ3 is 23.0 nM,
greatly enhanced bindings to αvβ3 were found with the micelle and SCKs, whose IC50
values were determined to be 1.38 nM and 0.49 nM, respectively.
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Scheme 4. Graphic representation of the synthesis KCRGDC-labeled micelles and SCKs by post-labeling 5-FAM-KCRGDC onto micelles
with PEG-COOH functionalities.

Table 4.

Characterization data and IC50 values of 5-FAM-KCRGDC-labeled

nanoparticles by post-labeling KCRGDC onto micelles with PEG-COOH on the surface.
entry

Samples

DTEM
nm

Naggr.

13

Micelle-5-FAM-KCRGD

26 ± 3

825

14

SCK-5-FAM-KCRGD
(50% crosslnked)

26 ± 3

825

Purification
method

Peptide
per NP2

IC50 (nM)a
αvβ 3

Sephadex ®
G75
(superfine)
SEC column

170

1.38

170

0.49

a

IC50 values for micelle/SCKs were measured to be the concentrations of the
nanoparticles in units of nM.

Conclusions
Methods to develop shell crosslinked nanoparticles bearing cyclic KCRGDC
peptide as the nanoscale antagonist to αvβ3 integrin were described in this study.
Nanoparticles labeled with KCRGDC prepared from post-labeling the 5-FAM-KCRGDC
peptide onto micelle/SCKs assembled from HOOC-PEG30004.0-g-DOTA-lysine3.2-gPAA58.8-b-PS71 showed much better binding affinities to αvβ3 than those nanoparticles
prepared from pre-labeling the NH2-PEG5000-5-FAM-KCRGDC to amphiphilic PAA-bPS block copolymers. It is hypothesized that when the NH2-PEG5000-5-FAM-KCRGDC
was pre-attached to the polymer, the majority of the peptide is buried underneath the
shell layer during the course of self-assembly, leading to low accessibility to bind to
outside integrins.

With good integrin αvβ3 binding affinity and selectivity, good

biodistribution which has been reported172, as well as with the DOTA-lysine serving as
the chelator of radiometals for imaging for PET imaging, these nanoparticles possess
potential to be developed into nanoscale diagnostic and therapeutic agent delivery
vehicles.
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CHAPTER 5

Concluding Remarks and Future Directions
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Radiolabeled receptor-binding peptides have emerged as an important class of
radiopharmaceuticals for

diagnostic imaging and cancer

therapy.176 Following

radionuclide labeling the specific receptor-binding properties of the ligand can be
exploited to guide the radioactivity to tissues expressing a particular receptor. This
dissertation reports on the development of integrin αvβ3–targeting radiopharmaceuticals
for medical imaging applications from the perspective of both the radiometal-labeled
chelator as well as the targeting peptide. Several macrocyclic copper(II) chelators have
been studied with the goal of improving kinetic and in vivo stability. Structurally diverse
bifunctional RGD (arginine-glycine-aspartic acid) peptides were investigated for αvβ3
integrin affinity in vitro and in vivo. The goal of accomplishing higher binding affinity
through multivalency has been pursued by evaluating the binding affinity of
nanoparticles presenting multiple peptides on their surface.
Copper radionuclides have been the subject of considerable research effort
because they offer a varying range of half-lives and positron energies, making them
useful for diagnostic imaging and/or targeted radiotherapy. Ensuring the stability of metal
complexes in vivo remains a challenge in the development of radiometal-based
radiopharmaceuticals and significant research effort has been devoted to the
development of ligands which can stably chelate copper isotopes.57, 177 To design crossbridged chelators that complex Cu(II) with faster kinetics while retaining the high in vivo
stability of CB-TE2A, different ring sizes of cross-bridged tetraazamacrocycles were
designed. Optimal radiolabeling conditions were established for the

64

Cu-labeled

radiometal chelators, and their in vivo biodistribution and metabolism was studied in
normal rats. First, a dicarboxylate analog of Springborg’s trimethylene-cross-bridged
cyclen64, 4,10-bis-(carboxymethyl)-1,4,7,10-tetrazazabicyclo[5.5.3]pentadecane (C3BDO2A), exhibited high in vitro stability, which unfortunatly did not translate to high in vivo
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stability. A two-carbon cross-bridged dicarboxylate analog of homocyclen, 4,11-bis(carboxymethyl)-(1,4,8,11-tetraazabicyclo[6.5.2]pentadecane (CB-TR2A), has the same
ring sizes as C3B-DO2A arranged in a different conformation. This compound did not
have the same high in vitro stability as Cu-C3B-DO2A, but had better in vivo stability.
The triazaamacrocyclic chelator 1,4,7-triazacyclononane-N,N’,N’’-triacetic acid (NOTA)
has been used in radiopharmaceuticals with suggested high in vivo kinetic stability.66, 178
No study of the Cu-chelator complex alone has been reported in the literature, so the
stability of 64Cu-NOTA was studied.
Previously in vitro inertness of copper chelators has been investigated as a
convenient indicator of in vivo stability,77 but this did not hold for the Cu-chelators studied
here. Many parameters control the behavior of radiopharmaceuticals in biological media,
and some of them cannot be easily predicted, requiring in vivo studies. The in vivo
stability of these complexes could be further evaluated by examination of the
radiometabolites and determination of the extent of transchelation to proteins.
Furthermore, a macrocyclic chelator with rapid complexation kinetics which also
demonstrates kinetic inertness comparable to the previously studied

64

Cu-CB-TE2A

under physiological conditions has not yet been identified. Research in developing Cu(II)
chelators with even greater stability is clearly warranted.
Integrin αvβ3 is upregulated in tumor vasculature, osteoclasts, and areas of
collateral circulation following ischemic injury.28 A series of structurally diverse
bifunctional RGD (arginine-glycine-aspartic acid) peptides were investigated for αvβ3
affinity in vitro and in vivo—lactam-cyclized, disulfide-cyclized, and linear RGD
derivatives and a lactam-cyclized control peptide. The RGD-peptides and the control
RAD-peptide were screened for integrin αvβ 3 binding affinity and specificity compared to
αvβ 5 and αIIbβ 3 in a competitive binding assay with each integrin’s native ligand. A
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lactam-cyclized peptide (c(RGDyK)) demonstrated higher affinity for αvβ3 than disulfidecyclized (KCRGDC) or linear peptide (GRGDS). Disulfide-cyclized peptides exhibit the
best selectivity of the ligands investigated. A control, lactam-cyclized peptide (c(RADyK))
has low affinity for all three integrins. Extent of internalization of the 64Cu-DOTA-peptides
in αvβ 3-positive U87MG human glioblastoma cells was determined. Uptake of RGD
peptides could be blocked by high doses of unlabeled peptide. Internalization of the
control peptide was minimal, although specific surface binding was observed. Disulfidelinked KCRGDC exhibited the best in vitro behavior—binding affinity, selectivity, and
internalization.
Biodistribution studies of the three

64

Cu-DOTA-RGD peptides in U87MG tumor-

bearing nu/nu mice showed rapid uptake and retention of the

64

Cu-labeled peptides in

tumor with good tumor:blood and tumor:muscle ratios. At 4 h post-injection tumor:muscle
ratios for all three compounds were similar, but 64Cu-DOTA-c(RGDyK) had a significantly
higher tumor:blood ratio (p< 0.001). Uptake of

64

Cu-DOTA-c(RGDyK) can be blocked by

co-administration of high doses of unlabeled peptide. Blocking of
and

64

Cu-DOTA-KCRGDC

64

Cu-DOTA-GGRGDS uptake at 1 h was not attained with either co-injection or pre-

injection (15 min or 1 h) of cold peptide. Further in vivo investigation is warranted to
demonstrate targeting specificity of the peptides along with investigation of a different
peptide as a negative control.
Polyvalency is known to have a profound effect on receptor-binding affinity and in
vivo kinetics of radiolabeled multimers. The goal of accomplishing higher binding affinity
through multivalency has been pursued by evaluating the binding affinity of SCK
nanoparticles presenting multiple RGD peptides on their surface. Micelles and shell
crosslinked nanoparticles (SCKs) prepared from poly(acrylic acid)-b-polystyrene (PAA-bPS) were labeled with the disulfide-cyclized peptide KCRGDC and studied as nanoscale
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agents for non-invasive imaging and targeted drug delivery. The SCKs produced have a
robust structure due to the covalent crosslinking reaction and have controllable sizes
ranging from 10 to 200 nm.179 Difficulties encountered in obtaining nanoparticles with
high levels of bioavailable radiometal macrocyclic chelator and targeting peptide on the
surface led to a systematic study of methods of shell functionalization and particle
purification with chemical, physical, and biological evaluation of each compound. With
the good cell targeting capabilities, good biodistribution been reported,172 as well as with
the DOTA-lysine acting as the chelator of radiometals for imaging for PET imaging,
these nanoparticles possess good potential to be developed into nanoscale diagnostic
and therapeutic agent delivery vehicles.
The development of radiometal-labeled peptides is a relatively slow process, thus
in this work optimization of various aspects was studied in parallel. This dissertation
contains many disappointing results, but the data are very relevant in that they suggest
different properties of chelator structure-activity to consider in future designs and new
directions in the synthesis and characterization of nanoparticles for targeted imaging and
drug delivery. Each chapter presents a small contribution, but the knowledge gained
from these studies can be taken together to produce radiopharmaceuticals with optimal
properties—high in vivo stability, high target uptake with low uptake in non-target
tissues, and rapid blood clearance preferably through renal excretion.
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Chapter 2 Supplemental Information
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Experimental Section
Collaborators. The experimental procedures for work related to Chapter 2 but
performed by collaborators are included here. Synthesis of C3B-DO2A was performed
by Dr. Riccardo Ferdani, CB-TR2A by Yijie Peng (University of New Hampshire,
Durham, NH)75 and NOTA by Elizabeth Garcia (UNH). Synthesis of all

nat

Cu(II)-chelator

complexes and their characterization was carried out at UNH in the laboratory of Dr. Ed
Wong. The Cu-CB-TR2A work has been reported in the doctoral dissertation of
Antoinette Odeendaal (UNH).76 X-ray crystallography was done in the laboratory of Dr.
Arnold Rheingold at the University of California—San Diego (La Jolla, CA); Cu-CB-TR2A
structure solved by James Golen. Dr. Thad Wadas was responsible for radiochemistry
involving CB-TR2A.
Materials and methods. Unless otherwise specified all chemicals were
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) and used as received.
Cyclen was purchased from Macrocyclics (Dallas, TX). Copper chloride (CuCl2) was
purchased from Johnson Matthey (West Deptford, NJ). All solutions were prepared using
water which had been distilled and then deionized (18 MΩ/cm2) by passing through a
Milli-Q water filtration system (Millipore Corp., Bedford, MA).
Infrared spectra were obtained as KBr pellets on a Nicolet MX-1 FTIR
spectrophotometer. Electronic spectra were recorded on a Carey 50 Bio UV/Vis
spectrophotometer. NMR spectra were taken using a Varian 300 MHz instrument and
referenced against internal trimethylsilane. ES-MS was accomplished using a Waters
Micromass ZQ (Millford, MA). Elemental analyses were carried out by Galbraith
Laboratories, Inc. (Knoxville, TN).
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Synthesis of C3B-DO2A. CB3-DO2A (5) was synthesized according to the
scheme shown in Scheme 1. Note that compound 3 was synthesized according to a
procedure previously published by Springborg et al. in 1995.65

TsO

Ts
NH HN

NH

TsCl
2 °C rt, 4 h
pyridine
(90%)

NH HN

N

N

OTs

Ts

Na2CO3, CH3CN
reflux, 6 d
(used for next step
with no purification)

HN

Ts

N

N

N

N

Ts
2

1

HBr/CH3COOH
reflux, 3 d
(21%)

OH
N

N

N

N

O

O
HO

TFA, CH2Cl2

N

N

N

O

O
rt, 3 d
(98%)

5

N

ButO

H

CO2But
OBut Br
Na2CO3, MeCN
(95%)

N

N

N

N
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Scheme 1. Synthesis of CB3-DO2A.

Briefly, cyclen was treated with 2 equivalents of p-toluene-sulfonyl chloride (TsCl) in
pyridine: the only product obtained was the 1,7-bis- tosylated derivative 1. The 3-carbon
cross bridge was then introduced by alkylation of the 2 secondary nitrogen atoms with 1
equivalent of 1,3-propanediol di-p-tosylate. Compound 2 was used in the following step
with no further purification: the protecting tosyl groups were removed upon refluxing 2 in
a HBr/CH3COOH mixture for 3 days. Recrystallization of the crude product yielded
compound 3 that was alkylated with 2 equivalents of tert-butyl bromoacetate. The final
product was obtained by removing the tert-butyl protecting groups in TFA/CH2Cl2.
4,10-bis-(carbo-tert-butoxymethyl)-1,4,7,10tetrazazabicyclo[5.5.3]pentadecane (4). Compound 3*3HBr (0.45 g, 1.0 mmol) was
dissolved in acetonitrile (25 mL) and then Na2CO3 (0.45g, 4.2 mmol) and tert-butyl

104

bromoacetate (0.34 mL, 2.3 mmol) were added and the reaction was heated to 60 °C for
3 days. After cooling, the solid was filtered off and the solution was evaporated under
reduced pressure. The crude was dried at the high vacuum pump and then triturated
with ethyl ether to give 4 in a 95% yield. 1H-NMR (DMSO-d6, 300 MHz): δ 1.32 (s, 18H,
C(CH3)3), 1.68 (m, 2H, NCH2CH2CH2N), 2.65-3.05 (m, 20H, NCH2CH2N and
NCH2CH2CH2N), 3.38 (s, 4H, NCH2C(O)).

13

C NMR (DMSO-d6, 75 MHz): δ 21.4, 28.5,

50.2, 53.3, 54.1, 55.8, 81.0, 171.4. MS (ESI+): m/z 441.1 (MH+), 385.1 (MH+- 1tBu),
329.1 (MH+- 2tBu).
4,10-bis-(carboxymethyl)-1,4,7,10-tetrazazabicyclo[5.5.3]pentadecane

(5).

Compound 4 (0.47 g, 1.1 mmol) was dissolved in a 1:1 mixture of dichloromethane (15
mL) and trifluoroacetic acid (15 mL) and the reaction was stirred at room temperature
under argon for 3 days. The solvent was then evaporated and the remaining oil was
dissolved in ethanol and slowly precipitated with ethyl ether. The final compound, CB3DO2A (5) was obtained, after drying at the high vacuum pump) as a slightly off-white
solid in a 98% yield. 1H-NMR (D2O, 300 MHz): δ 1.82 (m, 2H, NCH2CH2CH2N), 2.953.25 (m, 20H, NCH2CH2N and NCH2CH2CH2N), 3.61 (s, 4H, NCH2C(O)). 13C NMR (D2O,
75 MHz): δ 18.2, 51.7, 53.8, 53.9, 60.2, 173.1. MS (ESI+): m/z 329.1 (MH+). Elem.
analysis: calcd for C15H28N4O4*1.4 NaCl: C 43.92, H 6.88, N 13.64; found: C 43.94, H
6.92, N 13.30.
Synthesis of Cu-C3B-DO2A. An amount of 100 mg (0.203 mmol) of the ligand
(5) as a trifluoroacetate salt was combined with 75 mg (0.203 mmol) of Cu(ClO4)2•6H2O
in 8 mL of 95% ethanol. The pH was adjusted to 8.5 with 0.1 N NaOH. The suspension
was refluxed under nitrogen for 24 h to give a dark blue solution. After thorough removal
of volatiles under reduced pressure, a dark-blue sticky solid was obtained. This was
extracted with 4 mL methanol and centrifuged. The supernatant was then placed in vials
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inside a glass container for diethylether diffusion. A total crop of 75 mg of dendritic darkblue crystals formed. Elem. analysis: calcd for C15CuH26N4O4•1.33NaClO4•1.33H2O: C
31.24, H 5.01, N 9.71, Cl 8.18%. Found: C 31.05, H 5.21, N 9.45, Cl 8.06%. Electronic
spectrum (aq.) λmax 614 nm (ε = 84.6 M-1cm-1). FT-IR (KBr) νCOO 1687, 1616 cm-1. X-ray
crystals were grown from a hexafluoro-i-propanol solution upon diethylether diffusion.
Synthesis

of

CB-TR2A.

The

4,11-bis(carbo-tert-butoxymethyl)-1,4,8,11-

tetraazabicyclo[6.5.2]pentadecane was prepared from homocyclen according to the
procedure of Peng (Scheme 2).75, 180
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Scheme 2. Synthesis of CB-TR2A.75
Synthesis of Cu-CB-TR2A.76 A solution of 4,11-bis(carbo-tert-butoxymethyl)1,4,8,11-tetraazabicyclo[6.5.2]pentadecane (96.0 mg, 0.2179 mmol) in trifluoroacetic
acid (3.4 mL, 0.046 mol) and CH2Cl2 (3.4 mL) was stirred under N2 for 2 days. The
reaction mixture was then concentrated under aspirator pressure and the residual
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solvent was removed under vacuum to give 0.1635 g (0.2179 mol, 100%) of CB-TR2A
as a brown oil containing 3.7 equivalents of TFA by mass. To the solution of CBTR2A•3.7 TFA in 95% EtOH (15 mL) was added Cu(ClO4)2•6H20 (135.5 mg, 0.3657
mmol) and the pH of the reaction mixture was adjusted to 8 with 1 M NaOH. The
reaction was then refluxed under N2 for approximately 23 hours. The reaction mixture
was centrifuged and the supernatant collected and concentrated down under aspirator
pressure. Residual solvent was removed under vacuum to give 263.7 mg of a blue solid.
The solid was dissolved in 95% EtOH (15 mL) and the blue solution was placed in a
diethylether diffusion chamber. A powdery blue solid was collected to give 55.3 mg
(44%) of Cu•CB-TR2A•2(H20)•1.2(NaClO4). Elem. analysis: calcd for Cu(C15H26N4O4)•
2(H20)•1.2NaClO4: C, 31.45; H, 5.28; N, 9.78; Cl, 7.43. Found C, 31.49; H, 5.14, N, 9.68,
Cl, 7.10; IR (KBr) 3536, 3490, 3430, 3394, 3364, 1610, 1485, 1437, 1397, 1320, 1098,
631 cm-1. UV-Vis (H20) λmax 608 (ε = 32.1 M-1cm-1); Cyclic voltammetry conducted in 0.1
sodium acetate: indicated a quasi-reversible reduction with Eρ = -0.950 V (Ag/AgCl). A
0.13 M solution of Cu•CB-TR2A•2(H20)•1.2(NaClO4) in 95% EtOH was placed in a
diethylether diffusion chamber. Plate-like blue crystals were collected for X-ray structural
analysis, which yielded an empirical formula of Cu•CB-TR2A•H20•NaClO4.
Synthesis of NOTA. Pendant arming of 1,4,7-Triazacyclononane (TACN) was
achieved by using adapted procedure of functionalization of cross-bridged cyclams.181
Then, the elimination of t-butyl groups was carried out with approximately 600
equivalents of trifluoroacetic acid (TFA) (Scheme 3).
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Scheme 3. Synthesis of NOTA.

1,4,7-Triazacyclononane-1,4,7-tri-tertbutylacetate. Compound 3 (0.113 g,
0.875 mmol) was dissolved in MeCN (4.0 mL). Anhydrous Na2CO3 (0.283 g, 2,67 mmol)
and t-butyl bromoacetate(0.509 g, 2.61 mmol) were added sequentially to the solution.
The mixture was heated and stirred under N2 at 50 °C for 24 h. Then, solvent was
removed and the yellow residue was dissolved in cold solution of 20 % aq NaOH (30
mL). Keeping an ice bath temperature below 5 °C, solution extractions with cold CHCl3
(3× 50 mL), organic layers were collected and dried with NaSO4. Chloroform was
removed to give (0.308 g, 75%). 1H NMR (400 mHz, CDCl3; TMS): δH 3.33(6H, s),
2.87(12H, s), 1.45(27H, s).
1,4,7-Triazacyclononane-1,4,7-tri-acetic acid. Compound 8 (0.308 g,
0.653mmol) was dissolved in TFA (29 mL) and reflux for 24 hours under N2. The solution
was concentrated to gave brownish crude (0.446 g) which was then triturated with Et2O
(2× 50 mL). Evaporation of Et2O produced yellow brownish solid (0.390 g). Final product
was dissolved in warm MeOH (20 mL) and then cooling down to room temperature
allowed the precipitation of white crystals. 1H NMR (400 mHz, D2O; MeCN): δH 3.35 (6H,
s), 3.40 (12H, s); 13C{1H} NMR (500 mHz, D2O; MeCH): δC 173.5 (CCarbonyl) , 58.14
(C1(Ethylene)), 50.96 (C2(Ethylene)).
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Synthesis of Na[Cu-NOTA]. This compound was synthesized by a modified
version of the method reported by Wieghardt et al. in 1982.72 An amount of 0.16 mmol of
NOTA (as the trifluoroacetate salt) and an equimolar amount of CuCl2•2H2O (28 mg)
was dissolved in 0.40 mL water. The solution pH was adjusted to neutral using 0.1N
NaOH, followed by addition of 1 mL of ethanol. After cooling overnight at 0°C, light-blue
crystals formed.
Acid-decomplexation studies. The acid inertness assay was carried out for
each of the Cu(II)-ligand complexes, according to previously published methods.77
Briefly, a cuvette containing a sample of the complex in aqueous HCl was monitored by
its time-dependent electronic spectrum in a Cary 50 spectrophotometer. Cu-C3B-DO2A
was found to be inert to 5 M HCl at both 60 °C and 9 0 °C for at least one day. In 12 M
HCl at 90 °C, it decomplexed with a pseudo-first order half life of 7.2(7) days. Cu-CBTR2A was determined to have a half-life of 10.8(4) h in 5 M HCl at 30 °C. Cu-NOTA was
found to be inert to 1 M HCl at both 30 °C and 60 ° C for at least one day but
decomplexed within minutes in 5 M HCl at 30 °C.
Electrochemical studies. This assay was carried out for each of the Cu(II)ligand complexes, according to previously published methods.77 Briefly, a 3 mM solution
of the complex in 0.1 N NaOAc was examined in a BAS 100B Electrochemical Analyzer
using a glassy carbon working electrode, a platinum wire auxiliary electrode, and a
Ag/AgCl reference electrode. CV sweeps were performed at 200 mV/s. For Cu-C3BDO2A an irreversible reduction peak was observed at ~ -1.03 V with a large copper
stripping peak upon reoxidation. A quasi-reversible reduction was seen at -0.95 V for
Cu-CB-TR2A. For Cu-NOTA irreversible reduction peaks were observed at ~ -0.9 and
-1.2 V along with a large copper stripping peak upon return scanning.
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Preparation of

64

Cu-CB-TR2A. Preparation of this compound was similar to

radiolabeling conditions for CB-TE2A.62,

79

To a 1.5 mL acid washed conical vial, was

added CB-TR2A (100 µL of a 17 mM solution in ETOH), 150 µL of absolute EtOH and
excess Cs2CO3. This solution was heated at 98 °C for 2-3 h. After cooling and
centrifugation,

64

CuCl2 was added (10 mCi, 2.5 mCi/µL). The solution was sealed,

vortexed, and incubated for 2 h with shaking at 98 °C . After cooling, radio-TLC was
performed on regular silica plates with an eluent mixture of 1:1 MeOH:10%NH4OAc.
Once 95+% was achieved, the supernatant was placed in a second 1.5 mL centrifuge
tube and heated to reduce the volume of EtOH. When the volume was reduced by 75%,
200 µL of NH4OAC (pH 7, 0.1 mM) was added to the remaining liquid and the resulting
solution was mixed and heated again for 15 minutes to remove any remaining EtOH.
The sample was again re-analyzed using the same TLC conditions.
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Experimental Procedures
Collaborators. The experimental procedures for work related to Chapter 3 but
performed by Yunpeng Ye are included here. Cells were cultured by Susan Adams and
Alex Zheleznyak. All cell implants and animal dissections were performed by Chris
Sherman. Small-animal imaging and post-imaging animal dissections were performed by
the Radiological Sciences Small Animal Imaging Facility staff.
Cyclo[Asp(OBut)-DTry(But)-Lys-Arg(Pbf)-Gly].

The

resin-bound

protected

peptide (H-Asp(OBut)-DTyr(But)-Lys-Arg(Pbf)-Gly-resin) was assembled manually from
H-Gly-2-chlorotrityl resin (1.0 g, 0.54 mmol/g) via Fmoc chemistry as described above.
The linear protected peptide H-Asp(OBut)-DTyr(But)-Lys-Arg(Pbf)-Gly-OH was cleaved
by mixing the resin with 1% TFA in dichloromethane (DCM) for 2 min. The filtrate was
added to a solution of pyridine (5 mL) / methanol (10 mL) and the resin was washed with
methanol (1x) and dichloromethane (3x). This cleavage procedure was repeated for 5
times. The combined filtrate was concentrated by evaporation. The product was
precipitated by adding water (100 mL) and collected by filtration. The linear peptide was
dissolved in DMF (20 mL) and added drop-wise into a solution of benzotriazole-1-yl-oxytris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP, 520 mg, 1.0 mmol), HOBT
(135 mg, 1.0 mmol), and DIEA (260 mg, 2.0 mmol) in DMF (80 mL) / DCM (720 mL).
The mixture was stirred overnight, concentrated, and washed with water to give the
crude

product

cyclo[Asp(OBut)-DTyr(But)-Lys(Dde)-Arg(Pbf)-Gly]

(ES-MS:

[MH]+

1148.3). The solid was dissolved in methanol (50 mL), followed by adding hydrazine (1
mL). The mixture was stirred for 15 min, concentrated, washed with water, and dried.
The product, cyclo[Asp(OBut)-DTyr(But)-Lys-Arg(Pbf)-Gly], was further purified by flash
column chromatography to afford the desired compound (320 mg, 60% yield) ES-MS:
[MH]+ 984.5.
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Cyclo[DTyr-Lys(DOTA)-Arg-Gly-Asp]. A mixture of tri-tert-butyl N’,N’’,N’’’,N’’’’dodecyltetraacetic acid (DOTA-(3OBut)-COOH) (114.6 mg, 0.2 mmol), the protecting
cyclic RGD obtained above (98.5 mg, 0.1 mmol), DIC (50.4 mg, 0.4 mmol), and HOBT
(27.0 mg, 0.2 mmol) was stirred in anhydrous DMF (5 mL) for 8 h and concentrated
under high vacuum. ES-MS confirmed the formation of DOTA-RGD peptide conjugation
([MH]+/[MH2]2+: 1538.7 / 770.4). The residue was dissolved in 4 mL of TFA/water (95 %)
and kept at room temperature for about 3h and the solution was concentrated. This step
was repeated for another time. Half of the crude product was purified by semipreparative HPLC. The desired fractions identified by ES-MS were combined and
lyophilized to afford the title compound (31 mg, ~40% yield). ES-MS: [MH2]2+ 503.7.
DOTA-Lys-cyclo(Cys-Arg-Gly-Asp-Cys)-NH2.
peptide

The

resin-bound

protected

Fmoc-Lys(Boc)-Cys(Acm)-Arg(Pbf)-Gly-Asp(OBut)-Cys(Acm)-NH-Rink

amide

resin was assembled manually from Fmoc-Rink amide resin (0.2 g, ~0.20 mmol/g) as
described above. Thallium trifluoroacetate (2 equiv) in DMF (5 mL) was added and the
mixture was swirled for 1.5 h. The resin was washed with methanol (2x) and DMF (3x).
The resin was swirled with piperidine in DMF (20 %) and washed with methanol (2x) and
DMF (5x). A mixture of DOTA(3OBut)-COOH (3 equiv), HOBT (3 equiv), and DIC (9
equiv) in DMF was added into the resin and swirled overnight. The mixture was filtrated
and washed with DMF (2x) and methanol (3x). The resin obtained was mixed with
TFA/water (95:5, 3 mL) for 2 and filtered. This step was repeated for another 3 times.
The filtrate was combined and concentrated to give the crude product. Similarly, HPLC
purification followed by both ES-MS and analytical HPLC identifications gave the title
compound (13 mg, ~20% yield). ES-MS: [MH2]2+ 532.6.
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Experimental Procedures
Collaborators. All nanoparticles were synthesized by Zicheng Li from polymer
precursors synthesized by Jinqi Xu, Andreas Nyström, Guorong Sun, and Zicheng Li in
the laboratory of Dr. Karen L. Wooley. Yongjian Liu, Aviv Hagooly and Tetsuya Mori
assisted with FPLC analysis. Mike G. Veith assisted with TEM imaging using the
facilities of the Department of Otolaryngology at Washington University in St. Louis.
General Materials and Methods. Nitrogen (99.99%) was used for polymerization.
All chemicals were purchased from Sigma-Aldrich and used without further purification
unless otherwise noted. Prior to use, styrene (St; 99%) and t-butyl acrylate (t-BA; 98%),
N,N,N′,N′,N′′-

purchased from Aldrich, were distilled over calcium hydride.
pentamethyldiethylenetriamine
copper(I)

bromide

(99.999%;

(PMDETA;
Aldrich),

99%),

ethyl-2-bromopropionate

trifluoroacetic

acid

(TFA;

95%),

(99%),
2,2′-

(ethylenedioxy)-bis(ethylamine) (97%), 1-(3′-dimethylaminopropyl)-3-ethylcarbo-diimide
methiodide (EDCI; 98%), palladium on carbon (10 wt% loading), N-hydroxysuccinimide
(NHS;

98%),

N-Hydroxysulfosuccinimide

sodium

salt

(sulfo-NHS;

98.5),

N,N′-

Dicyclohexylcarbodiimide (DCC; 99%), Succinic anhydride (99%), were used as
received. Supor 25 mm 0.1 µm Spectra/Por Membrane tubes (molecular weight cutoff
(MWCO) 3,500 or 6-8000 Da), purchased from Spectrum Medical Industries Inc., were
used for dialysis. Nanopure water (18 MΩ⋅cm) was acquired by means of a Milli-Q water
filtration system (Millipore Corp.; Bedford, MA). KCRGDC was custom synthesized by
Tianma Pharma Co., Suzhou, China, and used as received.

5-FAM-KCRGDC was

custom synthesized by Chengdu Kaijie Biopharmaceuticals Co. Ltd., Chengdu, China,
and was used as received. Poly(ethylene glycol) (PEG) and derivatives were purchased
from Rapp Polymere GmbH, Germany.
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Superfine Sephadex

®

G75 resin (bead

diameter: 20-50 µm; Fractionation range: 1000-50000 Da (Dextrans)) was purchased
from GE Healthcare and was used to purify aqueous nanoparticle samples.
1

H NMR spectra were recorded on a Varian 300 MHz spectrometer interfaced to a

UNIX computer using Mercury software. Chemical shifts are referred to the solvent
proton resonance. Infrared spectra were acquired on a Perkin-Elmer Spectrum BX FTIR instrument using KBr pellets.
Absolute molecular weight and molecular weight distribution were determined by
Gel Permeation Chromatography (GPC). GPC was performed on a Waters 1515 HPLC
system (Waters Chromatography Inc., Medford, MA), equipped with a Waters 2414
differential refractometer, a PD2020 dual-angle (15° and 90°) light scattering detector
(Precision Detector, Inc.), and a three-column series PL gel 5 µm Mixed columns
(Polymer Laboratories Inc.). The system was equilibrated at 35 °C in anhydrous THF,
which served as the polymer solvent and eluent (flow rate set to 1.00 mL/min then
determined gravimetrically). All instrumental calibrations were conducted using a series
of nearly monodispersed polystyrene standards. Data were collected upon an injection
of a 200 µL of polymer solution in THF (ca. 5.0 mg/mL), and then analyzed using
Discovery 32 software (Version, Precision Detectors Inc). Inter-detector delay volume
and the light scattering detector calibration constant were determined by calibration
using a nearly monodispersed polystyrene standard (Pressure Chemical Co., Mp = 90
kDa, Mw/Mn < 1.04).

The differential refractometer was calibrated with standard

polystyrene reference material (SRM 706 NIST), of known specific refractive index
increment dn/dc (0.184 mL/g). The dn/dc values of the analyzed polymers were then
determined from the differential refractometer response.
Differential scanning calorimetry (DSC) measurements were performed with a
DSC822e instrument (Mettler-Toledo, Inc.) in a temperature range of -100 to 180 °C with
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a ramp rate of 10 °C/min under nitrogen.
STARe software (Mettler-Toledo, Inc.).

Data were acquired and analyzed using

The glass transition temperature, Tg, was

determined at the midpoint of the inflection tangent upon the third heating scan.
Samples for transmission electron microscopy (TEM) measurements were diluted
with 1 wt% of phosphotungstic acid (PTA) stain solution (v/v, 1:1). Carbon grids were
exposed to oxygen plasma treatment to increase the surface hydrophilicity. Micrographs
were collected at 100,000 magnifications. The number average particle diameters (Dav)
and standard deviations were generated from the analysis of a minimum of 150 particles
from at least three different micrographs.
The average heights for the nanoparticles were determined by performing
tapping-mode AFM under ambient conditions in air. The AFM instrumentation consisted
of a Nanoscope III BioScope system (Digital Instruments, Veeco Metrology Group;
Santa Barbara, CA) and standard silicon tips (type, OTESPA-70; L, 160 µm; normal
spring constant, 50 N/m; resonance frequency, 246-282 kHz).

Samples for AFM

imaging analysis were prepared through spin-coating c.a. 2.0 µL of the nanoparticle
solution (typical concentration: 0.2 mg/mL) onto freshly cleaved mica plates (Ruby clear
mica, New York Mica Co.) and allowed to dry freely in air. The number-average particle
heights (Hav) values and standard deviations were generated from the sectional analysis
of more than 150 particles from several different regions.
Hydrodynamic diameters (Dh) and size distributions for the SCKs in aqueous
solutions were determined by dynamic light scattering (DLS).

The DLS instrument

consisted of a Brookhaven Instruments Limited (Worcestershire, U.K.) system, including
a model BI-200SM goniometer, a model BI-9000AT digital correlator, a model EMI-9865
photomultiplier, and a model 95-2 Ar ion laser (Lexel Corp., Farmindale, NY) operated at
514.5 nm. Measurements were made at 20 °C. Prior to analysis, solutions were filtered
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through a 0.22 µm Millex GV PVDF membrane filter (Millipore Corp., Medford, MA) and
then centrifuged in a model 5414 microfuge (Brinkman Instruments, Inc., Westbury, NY)
for 10 min to remove dust particles. Scattered light was collected at a fixed angle of 90°.
The digital correlator was operated with 522 ratio spaced channels, and initial delay of 5
µs, a final delay of 100 ms, and a duration of 10 min. A photomultiplier aperture of 400
µm was used, and the incident laser intensity was adjusted to obtain a photon counting
of between 200 and 300 kcps.

Only measurements in which the measured and

calculated baselines of the intensity autocorrelation function agreed to within 0.1% were
used to calculate particle sizes. The calculations of the particle size distributions and
distribution averages were performed with the ISDA software package (Brookhaven
Instruments Company), which employed single-exponential fitting, cumulants analysis,
non-negatively constrained least-squares (NNLS) and CONTIN particle size distribution
analysis routines. All determinations were made in triplicate. The results were analyzed
by UNICORN 3.10.11.
Fast protein liquid chromatography (FPLC) was performed on an AKTA (GE)
system, including a P-920 pump, Columns of Superose 12 10/300 GL, and a UV
detector with 254 nm wavelength. The eluent was 20 mM HEPES with 150 mM NaCl
and flow rate was 0.8 mL/min. UV- vis spectra were acquired on a Varian Cary 1E UVvis system (Varian, Inc., Palo Alto, CA) using polystyrene cuvettes.
General Procedures for Diblock Copolymer Preparation. Poly(t-butyl
acrylate) (PtBA) homopolymer was first prepared by atom transfer radical polymerization
(ATRP).

PtBA was further used as a macroinitiator to grow the second block,

polystyrene (PS), through the same polymerization method, to afford poly(t-butyl
acrylate)-b-polystyrene (PtBA-b-PS). The resulting PtBA-b-PS was then treated with
trifluoroacetic acid in methylene chloride to remove the protecting t-butyloxy groups, as
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monitored by 1H NMR. After the removal of the solvent, the residue was dissolved in
tetrahydrofuran and purified by dialysis against water. PAA-b-PS diblock copolymer was
obtained after lyophilization.
PtBA61-b-PS34: 0.83 g (67% yield).

GPC

Mn = 11,600 Da from GPC, Mw/Mn = 1.08. Tg

(PtBA) = 53 °C, T g (PS) = 82 °C. IR: 3433, 3100-2870, 1943, 1870, 18 02, 1734, 1601,
1493, 1452, 1392, 1368, 1259, 1164, 846, 757, 704, 542 cm-1.

1

H NMR (CDCl3, 300

MHz, ppm): δ 7.25-6.27 (m, 5Ar-H), 2.37-2.02 (br, CH of the polymer backbone), 1.991.08 (br, CH2 of the polymer backbone and C (CH3)3).

13

C NMR (CDCl3, 75 MHz, ppm):

δ 174.0, 125.8-129.7, 108.1, 80.3, 40.4-41.5, 35.5-36.8, 27.9.
PAA61-b-PS34: 0.44 g (88% yield). Mn = 8,200 Da. Tg (PAA) = 126 °C, T g (PS) =
105 °C. IR: 3405, 3047-2914, 1942, 1875, 1722, 160 1, 1492, 1450, 1245, 762, 701 cm1 1

. H NMR (THF-d8, 300 MHz, ppm): δ 11.6-10.0 (br, COOH), 7.25-6.30 (m, 5Ar-H), 2.60-

2.20 (br, CH of the polymer backbone), 2.15-1.10 (br, CH2 of the polymer backbone). 13C
NMR (THF-d8, 75 MHz, ppm): δ 177.5, 124.8-129.5, 41.5-42.6, 35.5-37.2.
PtBA60-b-PS60: 4.1 g (80% yield);

GPC

Mn = 14,000 Da, Mw/Mn = 1.15. Tg (PtBA) =

49 °C, T g (PS) = 93 °C. IR: 3430, 3100-2890, 1940, 1860, 18 00, 1734, 1600, 1490,
1452, 1390, 1370, 1260, 1164, 845, 756, 700, 540 cm-1.

1

H NMR (CDCl3, 300 MHz,

ppm): δ 7.23-6.24 (m, 5Ar-H), 2.35-2.05 (br, CH of the polymer backbone), 1.98-1.07 (br,
CH2 of the polymer backbone and C(CH3)3).

13

C NMR (CDCl3, 75 MHz, ppm): δ 173.6,

126.0-130.2, 108.0, 80.1, 40.6-41.7, 35.5-36.6, 28.0.
PAA60-b-PS60: 1.1 g (90% yield). Mn = 10,600 Da. Tg (PAA) = 126 °C, Tg (PS) =
104 °C. IR: 3407, 3040-2915, 1940, 1873, 1722, 1600 , 1492, 1453, 1242, 760, 700 cm1. 1H NMR (THF-d8, 300 MHz, ppm): δ 12.6-10.4 (br, COOH), 7.20-6.35 (m, 5Ar-H),
2.58-2.18 (br, CH of the polymer backbone), 2.20-1.10 (br, CH2 of the polymer
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backbone).

13

C NMR (THF-d8, 75 MHz, ppm): δ 177.0, 125.3-130.5, 42.0-42.9, 35.7-

37.0.
Preparation of NH2-PEG5000-5-FAM-KCRGDC. Three steps were involved to
prepare NH2-PEG5000-5-FAM-KCRGDC, as shown in Scheme 1. BocNH-PEG5000-NH2
(compound 1, 300 mg, 0.0600 mmol), was dissolved in 13 mL of dichloromethane and
stirred at room temperature for c.a. 0.5 h. Succinic anhydride (24.6 mg, 0.246 mmol)
and DIPEA (21.0 µL, 15.5 mg, 0.120 mmol) were added. The reaction mixture was
allowed to stir at room temperature for 24 h.

The reaction mixture was then

concentrated and precipitated into cold ether (40 mL) twice. The precipitate was dried
under vacuum to afford 238 mg of white solid as compound 2, BocNH-PEG5000NHCOCH2CH2COOH (yield 80%).
Compound 2 (201 mg, 0.0402 mmol) was dissolved in 10 mL of dichloromethane
and stirred at room temperature for c.a. 0.5 h. N-hydroxysuccinimide (23.6 mg, 0.205
mmol) and N,N′-Dicyclohexylcarbodiimide (43.7 mg, 0.211 mmol) were added.

The

solution was allowed to stir at room temperature for 24 h before being concentrated and
precipitated into cold ether (40 mL) twice. The precipitate was then dried under vacuum
to afford a white solid, compound 3 (151 mg, yield: 73%).
5-FAM-KCRGDC (40.6 mg, 0.0390 mmol) was dissolved in 5 mL of dry DMF, to
this solution were also added Compound 3 (104 mg, 0.0201 mmol) and DIPEA (10 µL,
7.3 mg, 0.057 mmol). The reaction mixture was allowed to stir at room temperature for
24 h. The reaction mixture was precipitated into cold ether (45 mL) once. The solid was
then dissolved in DCM and precipitated into cold ether (45 mL) twice to afford a yellow
solid as compound 4 (100 mg, yield: 80%).
Compound 4 (100 mg, 15.9 µmol) was dissolved in 6 mL of DCM. TFA (4.8 mL,
7.1 g, 62.3 mmol) was added.

The reaction mixture was allowed to stir at room
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temperature for 12 h, concentrated and precipitated into cold ether. The precipitate was
dried under vacuum to afford NH2-PEG5000-5-FAM-KCRGDC as a yellow solid (80 mg,
yield: 79%).

Scheme 1. Synthesis of NH2-PEG5000-5-FAM-KCRGDC.

General procedures for preparation of mPEG2000-g-PAA-b-PS Block Copolymers.
Grafting mPEG2000 onto PAA-b-PS involved the following: to a solution of PAA60-b-PS60
block copolymer in anhydrous (DMF), 1-[3′-(dimethylamino)propyl]-3-ethylcarbodiimide
methiodide (EDCI), and 1-hydroxybenzotriazole (HOBt) were added, and the reaction
mixture was allowed to stir for 1 h at room temperature. Then DIPEA and a solution of
monoamine terminated mPEG2000 in anhydrous DMF were added and the reaction
mixture was further stirred for 30 h at room temperature. The relative ratios of PAA60-bPS60 block copolymer/EDCI/HOBt/mPEG-NH2 were varied to alter the grafting densities,
whereby to achieve grafting densities of 2.5 and 5.5 mPEGs per macromolecule, the
stoichiometry were 1.0:3.5:3.5:3.5, and 1.0:7.0:7.0:7.0, respectively. The final grafted
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block copolymers were isolated by transferring the reaction mixtures to presoaked
dialysis tubing (MWCO 6000-8000 Da) and dialyzing against nanopure water for 4 d to
remove the organic solvent and the small molecular byproduct. The aqueous solutions
were then lyophilized to afford the products as white solid.

1

H NMR (CD2Cl2, 500 MHz,

ppm): δ 1.20-2.40 (br, -CH2- and -CH- of the polymer backbone), 3.34 (s, mPEG terminal
-OCH3 protons), 3.42-3.80 (br, mPEG backbone -OCH2CH2O- protons), 6.16-7.11 (br,
aromatic protons).
mPEG20002.5-g-PAA57.5-b-PS60. PAA60-b-PS60 (120.0 mg, 11.3 µmol), EDCI (11.8
mg, 39.6 µmol), HOBt (5.4 mg, 40.0 µmol), and monoamine terminated mPEG2000
(79.2 mg, 39.6 µmol) in anhydrous DMF (15.0 mL). Yield: 75%.
mPEG20005.5-g-PAA54.5-b-PS60. PAA60-b-PS60 (110.0 mg, 10.4 µmol), EDCI (21.6
mg, 72.8 µmol), HOBt (9.9 mg, 73.3 µmol), and monoamine terminated mPEG2000
(145.6 mg, 72.8 µmol) in anhydrous DMF (15.0 mL). Yield: 75%.
Preparation of mPEG2000-g-DOTA-lysine-g-PAA-b-PS Block Copolymers.

The

DOTA-lysine (a lysine derivative for 1,4,7,10-tetraazocyclododecane-N,N′,N′′,N′′′tetraacetic acid, DOTA) was grafted onto mPEG2000-g-PAA-b-PS by following a
procedure similar to that used to graft mPEG2000 (described above). To a solution of
mPEG2000-g-PAA-b-PS block copolymer (10.3 µmol) in anhydrous DMF (10.0 mL),
EDCI (11.6 mg, 39.1 µmol) and HOBt (5.3 mg, 39.3 µmol) were added and the reaction
mixture was allowed to stir for 1 h at room temperature. Then a solution of DOTA-lysine
(trifluoroacetic acid (TFA) salt, 23.1 mg, 39.2 µmol) and N,N-diisopropylethylamine
(DIPEA, 25.4 mg, 0.196 mmol) in anhydrous DMF (2.0 mL) was added and the reaction
mixture was further stirred for 30 h at room temperature.

The final grafted block

copolymers were isolated by transferring the reaction mixtures to presoaked dialysis
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tubing (MWCO 6000-8000 Da) and dialyzing against nanopure water for 5 d to remove
the organic solvent and the small molecular byproduct. The aqueous solutions were
then lyophilized to afford the products as white solid. Yield: 65%. 1H NMR (500 MHz,
CD2Cl2 with 2 drops of CF3CO2D, ppm): δ 1.20-2.40 (br, -CH2- and -CH- of the polymer
backbone, overlapped with DOTA-lysine protons), 2.40-2.70 (br, DOTA-lysine
macrocyclic protons), 3.34 (s, mPEG terminal -OCH3 protons), 3.42-3.80 (br, mPEG
backbone -OCH2CH2O- protons), 6.16-7.11 (br, aromatic protons).
Preparation of PEG-5-FAM-KCRGDC-g-mPEG2000-g-DOTA-lysine-g-PAA-b-PS
Block Copolymers. The PEG-5-FAM-KCRGDC was grafted onto mPEG2000-g-DOTAlysine-g-PAA-b-PS by following the procedures similar to used to graft mPEG2000 or
DOTA-lysine (described above). The relative ratio of mPEG2000-g-DOTA-lysine-g-PAAb-PS block copolymer/EDCI/HOBt/mPEG-NH2 was 1:20:20:4.

To a solution of

mPEG2000-g-PAA-b-PS block copolymer (0.80 µmol) in anhydrous DMF (7.5 mL), EDCI
(4.96 mg, 16.7 µmol) and HOBt (2.27 mg, 16.8 µmol) were added and the reaction
mixture was allowed to stir for 1 h at room temperature. Then a solution of PEG-5-FAMKCRGDC

(trifluoroacetic

acid

(TFA)

salt,

21.1

mg,

3.36

µmol)

and

N,N-

diisopropylethylamine (DIPEA, 100 mg, 0.85 mmol) in anhydrous DMF (2.0 mL) was
added and the reaction mixture was further stirred for 24 h at room temperature. The
polymer concentration of the reaction mixture was then adjusted to 1.00 mg/mL by
adding appropriate amount of DMF for future use. Micelles were directly prepared from
the reaction mixture and impurities were later removed by dialysis against nanopure
water in MWCO 50000 Da dialysis tubings.
Preparation

of

HOOC-PEG30004.0-g-DOTA-lysine3.2-g-PAA60-b-PS60

Block

Copolymer. Similar procedures were followed as mentioned above, except for the
attaching sequence, as shown in the scheme below: DOTA-lysine (tetra-t-butyl ester)
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was first grafted onto the block copolymer PAA60-b-PS60, solid polymer product, was
obtained by methods described above and the number of DOTA-lysine per polymer
chain was determined by 1H NMR (coupling efficiency 90%). To the DOTA-lysine(tetra-tbutyl ester)-g-PAA60-b-PS60 was then attached NH2-PEG3000-COOH, by pre-activating
the –COOH on the polymer chains, to afford HOOC-PEG30004.0-g-DOTA-lysine3.2-gPAA60-b-PS60 (coupling efficiency 80%).

Scheme 2. Preparation of HOOC-PEG30004.0-g-DOTA-lysine3.2-g-PAA60-b-PS60.
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General procedures for micelle assembly and SCK formation. To a solution of
the amphiphilic block copolymer (PAA-b-PS, mPEG2000-g-DOTA-lysine-g-PAA-b-PS or
PEG-5-FAM-KCRGDC-g-mPEG2000-g-DOTA-lysine-g-PAA-b-PS) in THF or DMF, (ca.
1.0 mg/mL in polymer concentration), an equal volume of nanopure water was added
dropwise via a syringe pump over 6 h. The reaction mixture was further stirred for c.a.
16 h at room temperature before transferring to a presoaked dialysis tubing (MWCO.
6,000-8,000 Da for PAA-b-PS; MWCO 50,000 Da for PEG-5-FAM-KCRGDC-gmPEG2000-g-DOTA-lysine-g-PAA-b-PS), and dialyzed against nanopure water for 4
days, to afford a micelle solution with the final polymer concentration of 0.20-0.30
mg/mL.
General procedures for the PAA Block Crosslinking to Form SCKs.

To a

solution of micelle in nanopure water, was added dropwise a solution of 2,2’(ethylenedioxy)bis(ethylamine) (c.a. 1.0 mg/mL) in nanopure water over 10 min. The
reaction mixture was stirred for c.a. 2 h at room temperature. To this solution, was
added

dropwise

via

syringe

pump

over

30

min,

a

solution

of

1-[3’-

(dimethylamino)propyl]-3-ethylcarbodiimide methiodide in nanopure water. The reaction
mixture was further stirred 20 h at room temperature before transferring to a presoaked
dialysis tubing, and dialyzed against nanopure water for 4 days, to remove all of the
impurities and afford the SCK solution. The nominal crosslinking extent (20% and 50%)
were based on the stoichiometry of the crosslinker (2,2’-(ethylenedioxy)bis(ethylamine))
to that of the carboxylic acids on the PAA domain. The general stoichiometry employed
to achieve 20% nominal crosslinking was 9:2.2:1 for carboxylic acid units : EDCI :
crosslinker, and to achieve 50% nominal crosslinking, the stoichiometry was 3.6:2.2:1.
General procedures for post-attaching KCRGDC/5-FAM-KCRGDC/PEG-5-FAMKCRGDC onto micelle/SCK nanoparticles. All micelle/SCK samples were pre-cooled
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to 4 °C. Sulfo-NHS aqueous solution was then added, and the containers were shaken
for c.a. 30 min. Freshly prepared EDCI aqueous solution was added and the reaction
containers were shaken for 1.5 h in a 4 °C refrigerator. Here, the pH values of the
solutions were adjusted to around 7.4 with pH 9.2 0.2 M phosphate buffer. KCRGDC/5FAM-KCRGDC/PEG-5-FAM-KCRGDC solutions were then added.

The pH of the

reaction solutions were finally adjusted to around 7.4 (optimal pH for the coupling
reaction to occur) and the reaction mixtures were kept shaking at 4 °C for 24 h. All
reaction mixtures were then dialyzed against pH 7.4 5 mM PBS (after treatment of
Chelax 100 resin) for 5 d.
Reduction of disulfide bond on KCRGDC-NP to thiol.

Excess DTT (DL-

dithiothreitol) was incubated with micelle/SCK nanoparticles labeled with the cyclic
KCRGDC at 45 °C for 1h (Scheme 3). The reaction mixture was then dialyzed against
nanopure water in pre-soaked MWCO 6-8000 Da dialysis tubing to remove unreacted
DTT and for later quantification of thiol groups by Ellman’s assay.

Scheme 3. Cleavage of disulfide bond on KCRGDC.

Ellman’s assay. Cysteine (26.0 mg) is dissolved into 10.00 mL of reaction buffer
(0.10 M sodium phosphate buffer, pH 8.0) to make the stock solution. Ellman’s reagent
(4.00 mg DTNB) was dissolved into 1.00 mL of reaction buffer. A series of cysteine
standard solutions with different concentrations are then prepared from the stock
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solution, with cysteine concentrations being 15.0 mM, 1.50 mM, 1.25 mM, 1.00 mM, 1.00
mM, 0.75 mM, 0.50 mM, 0.25 mM and 0.05 mM. The Ellman’s reagent solution was
then mixed with the cysteine standard solutions and the samples to be measured using
the following volumetric quantities: 983 µL buffer and 18 µL Ellman’s reagent for blank;
938 µL buffer, 18 µL of Ellman’s reagent, and 45 µL sample. After 15 minutes the
absorbance of each sample was measured at 412 nm.
Purifying aqueous nanoparticle samples using Sephadex® G75 gravity SEC
columns. Sephadex® G75 resin (superfine) (10 g) was pre-soaked in boiling water for
c.a. 30 min to form a gel. After cooling to room temperature, the resin was packed into a
glass column (30 cm × 2 cm) equipped with a stopcock. About 200 mL of the eluent
(150 mM PBS, pH ~ 7.4) was passed through the column prior to any sample loading.
For each run, c.a. 4 mL of nanoparticle samples (with polymer concentration around
0.20-0.30 mg/mL) was loaded.
spectrometry.

The separation process was monitored by UV

Columns were reused after being flushed with excess eluent.

The

desired fractions were collected and concentrated and solvent-exchanged into 5 mM
PBS by using Centricon (MWCO 10000 Da, Millpore, MA) tubes.
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APPENDIX IV

Sprague, JE; Peng, Y; Fiamengo, AL; Wooden, KS; Southwick, EA; Weisman, GR;
Wong, EH; Golen, JA; Rheingold, AL; Anderson, CJ. “Synthesis, characterization and in
vivo studies of

64

Cu(II)-labeled cross-bridged tetraazamacrocycle-amide complexes as

models of peptide conjugate imaging agents.” J. Med. Chem. 2007; 50 (10): 2527-2535.
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